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i 
Abstract 
Stem cell transplantation is under investigation to stimulate angiogenesis in patients with 
peripheral artery disease. To develop a cell-delivery platform that enhances cell retention 
and function post-transplantation, the response of human adipose-derived stem/stromal 
cells (ASCs) encapsulated within N-methacrylate glycol chitosan (MGC) hydrogels with 
or without integrin-binding RGD or IKVAV motifs was explored. ASC viability was 
enhanced in the MGC and MGC-RGD hydrogels relative to the MGC-IKVAV group 
under hypoxic (2% O2) culture conditions, with cell spreading and higher metabolic 
activity noted in MGC-RGD at 14 days. Analysis of angiogenic gene expression revealed 
similar patterns between all hydrogel groups, with higher levels of the pro-angiogenic 
factors HGF, VEGFA, ANGPTL4 and ANGPT2 in 3-D versus 2-D cultures. 
Characterization of the in vivo response following subcutaneous implantation in 
NOD/SCID mice showed enhanced ASC retention in MGC-RGD, with increased peri-
implant CD31+ cell recruitment in the ASC-seeded MGC and MGC-RGD hydrogels 
relative to unseeded controls. 
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Chapter 1  
1 INTRODUCTION 
1.1 Clinical Significance 
1.1.1 Peripheral Artery Disease (PAD) 
Affecting an estimated 800,000 Canadians and over 9 million Americans, peripheral 
artery disease (PAD) is prevalent in North America.1 PAD is the manifestation of 
systemic atherosclerosis resulting in the obstruction of arteries that supply blood to 
organs other than the heart, with the lower extremities being the most commonly affected 
site.1,2 Atherosclerosis is a progressive disease characterized by excessive accumulation 
of lipid deposits, fibrous tissue, and inflammatory cells in the lumen of arteries and 
arterioles.3 The build-up of atherosclerotic plaques in the peripheral arteries reduces 
oxygenated and nutrient-rich blood flow to vascular beds in the extremities, causing 
patients to develop disabling complications such as pain with walking (intermittent 
claudication; IC) and peripheral neuropathy.4 The significant restriction of blood flow to 
the periphery can result in critical limb ischemia (CLI)—the most severe form of PAD, 
which can lead to resting limb pain, non-healing ulcerations that are prone to infection, 
and tissue necrosis.2,5 
PAD has been termed a ‘silent’ cardiovascular disease because many patients do not seek 
treatment until the condition progresses to advanced stages, along with other 
cardiovascular comorbidities.1 While the incidence of PAD increases significantly with 
age, its prominent risk factors include smoking, diabetes mellitus, hypercholesterolemia, 
chronic kidney disease, hypertension, metabolic syndrome and obesity.1,6 Combined with 
the aging population, sedentary lifestyle and increasing burden of atherosclerotic risk 
factors, the incidence of PAD is expected to rise dramatically over the next 10 years.1 
1.1.2 Pathophysiology of PAD 
PAD pathophysiology is a chronic and complex process affecting the macro- and 
microvasculature of peripheral tissues.2 The blood supply from the abdominal aorta 
divides at the iliac artery to enter the legs, and then runs serially through the superficial 
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femoral artery in the thigh into the popliteal artery at the knee in a single continuous 
vessel with very few branches.7 In the majority of patients with symptomatic PAD, there 
is significant occlusion of the iliac, femoral and/or infrapopliteal arteries.8,9 A chronic 
state of ischemia is established due to reduced perfusion pressure in the distal 
vasculature.10,11 Compensatory mechanisms cause the peripheral arterioles to maximally 
vasodilate due to the chronic exposure to vasorelaxing factors, subsequently resulting in a 
lack of tone in the blood vessels (vasomotor paralysis).11 These structural and functional 
alterations result in the inability to regulate blood hydrostatic pressure, leading to 
endothelial cell (EC) damage and edema in the distal portion of the limb, further 
impairing the compromised microvasculature.5,11 While a healthy endothelium aids in the 
modulation of vascular tone and permeability, EC damage resulting from chronic 
ischemia increases free radical production, impairs nitric oxide (NO) regulation, causes 
inappropriate platelet activation and leukocyte adhesion, and contributes to the formation 
of microthrombi.5,11 Overall, blood flow abnormalities impair oxygen and nutrient 
exchange at the capillary level, leading to increased inflammation, apoptosis, and tissue 
necrosis.5 
1.1.3 Current Treatments for PAD 
The current treatments for PAD include lifestyle modifications and pharmacotherapy to 
improve cardiovascular risk factors, with advanced cases requiring invasive surgical or 
endovascular interventions such as balloon angioplasty, stenting, or surgical bypass to 
restore peripheral blood flow.4 While endovascular treatments or bypass grafting can 
improve arterial resistance, blood perfusion is often not fully restored in the affected 
limbs and post-operative edema is common due to the impaired distal 
microvasculature.12,13 Therefore, many patients with CLI are not candidates for surgical 
revascularization or endovascular angioplasty due to diffuse atherosclerosis, and limb 
amputation is required in ~25% of patients within the first year of diagnosis.14 
Amputation has a detrimental impact on the quality of life, and is associated with high 
morbidity and mortality rates.14 Perioperative mortality for below- and above-the-knee 
amputations is between 5-20%, with a two-year mortality rate of up to 30% post-
amputation.10,15 Furthermore, many survivors require a secondary amputation and less 
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than 50% of the patients recover full mobility.16 CLI also places a considerable economic 
burden on the healthcare system attributed to prolonged hospitalization, complex wound 
care, and invasive surgical procedures.17 Taken together, there is a critical need to 
develop improved therapies to treat CLI. 
1.2 In Vivo Response to Tissue Ischemia 
Under pathological conditions such as obstructive arterial disease, oxygenated blood and 
nutrient exchange is unable to meet the metabolic demands of the surrounding tissues.2 
As a result, the body initiates several compensatory mechanisms in an attempt to restore 
circulation to the ischemic tissues by inducing structural and functional changes in the 
existing vasculature, or by stimulating new blood vessel formation.2 
1.2.1 Angiogenesis 
Angiogenesis is a multi-step process involving the growth of new blood vessels from pre-
existing vessels through a series of stages including EC proliferation and migration, 
abluminal sprouting, and bridging of existing vessels.16 The process of angiogenesis is 
tightly regulated by key pro- and anti-angiogenic molecules that function to advance or 
regress blood vessels through the stroma (Table 1.1).18 In a model first proposed by Judah 
Folkman,19 the angiogenic switch is considered “off” when the effects of the pro-
angiogenic factors are balanced with those of the anti-angiogenic factors.18 However, 
local hypoxia, inflammation and impaired perfusion can act as triggering events, shifting 
the balance towards a more pro-angiogenic state.20 
Table 1.1. Key molecules that regulate pro- and anti-angiogenic response.18 
Pro-angiogenic molecules Anti-angiogenic molecules 
Vascular endothelial growth factor 
(VEGF) family 
Angiostatin (plasminogen fragment) 
Endostatin (collagen XVIII fragment) 
Fibroblast growth factor (FGF) family Angiopoietin-2 (Ang-2) 
Angiopoietin-1 (Ang-1) Thrombospondin-1, -2 (TSP-1, -2) 
Hepatocyte growth factor (HGF) Interferon-α, -β, -! (INF-α, -β, -!) 
Platelet-derived growth factor (PDGF) 
Matrix metalloproteinases (MMPs) 
Tissue inhibitor of metalloproteinases 
(TIMPs) 
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During ischemic injury, EC transcriptional responses are mediated by hypoxia-inducible 
factors (HIFs) that regulate the expression of pro-angiogenic, metabolic and cell cycle 
genes.20 Under high oxygen tension, prolyl hydroxylase (PHD) enzymes mark hypoxia 
inducible factor-1α (HIF-1α) for degradation through hydroxylation of 2 proline residues 
in its oxidation-dependent degradation domain (ODDD).20 However, under hypoxic (<5% 
O2) conditions, the activity of PHD enzymes is attenuated due to limited O2 and cofactor 
2-oxoglutarate required for the enzymatic functions.20,21 As a result, HIF-1α is stabilized 
and dimerizes with hypoxia inducible factor-1β (HIF-1β)/aryl hydrocarbon receptor 
translocator (Arnt).20 The entire complex translocates to the nucleus where it binds to 
hypoxia response element (HRE) and upregulates the transcription of over 60 known 
genes that influence EC proliferation, migration, and vascular growth.20 
Following the transcriptional changes mediated by HIF-1α, stromal cells within the 
injured tissues also secrete pro-angiogenic factors such as VEGF and FGF that activate 
cognate receptors on nearby ECs.22 Initially, ECs are destabilized by the disruption of 
cell-cell contacts through VEGF-mediated dissociation of vascular endothelial (VE)-
cadherin and Ang-2/Tie-2 interactions with neighbouring mural cells.23 In addition, 
VEGF activates ECs to form tip cells, which then guide the developing capillary sprout 
through the extracellular matrix (ECM).24 While the tip cell does not divide, the 
endothelial stalk cells that follow the migrational front undergo rapid proliferation 
stimulated by VEGF, FGF, HGF and transforming growth factor-α (TGF-α) to form a 
lumen.23,24 The tip cell guides the migration of the developing sprout along a gradient of 
soluble and matrix-bound VEGF.25 MMPs secreted by proliferating ECs mediate the 
remodeling of the ECM to facilitate the new vessel growth.26 Cell-cell linkages between 
nascent ECs are facilitated by the upregulation of adhesion molecules, including platelet-
derived endothelial cell adhesion molecule (PECAM or CD31).16,23 Stabilization of the 
growing vessel occurs through inhibition of EC proliferation by transforming growth 
factor-β (TGF-β), and upregulation of VE-cadherin strengthens the junctions between 
ECs.27 Lastly, PDGF facilitates the recruitment and proliferation of tissue-resident 
pericytes and vascular smooth muscle cells (SMCs) in order to support the new vessel 
through envelopment and matrix deposition, while Ang-1/Tie-2 mediates vascular 
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permeability.16,28 The newly formed capillaries, ~5-20 μm in diameter, fuse with existing 
vascular beds and blood flow commences.16 
1.2.2 Vasculogenesis 
Vasculogenesis is the de novo formation of blood vessels from EC precursor cells, or 
angioblasts.29  Until recently vasculogenesis was thought to occur only during embryonic 
development.29 However, in 1999, Asahara and Insner reported the existence of 
circulating human bone marrow (BM)-derived endothelial precursor cells (EPCs) that 
contribute to post-natal vessel formation.30 Post-natal vasculogenesis involves the homing 
of circulating EPCs to sites of ischemic injury, and the formation of new vessel networks 
through inosculation within advancing or regressing vessel networks.31,32 Growth factors 
and chemokines generated as a result of local cellular hypoxia, including VEGF, stromal 
cell-derived factor-1 (SDF-1), granulocyte/macrophage colony stimulating factor (GM-
CSF) and interleukin-8 (IL-8), recruit circulating EPCs to the site of ischemic injury to 
facilitate microvascular repair.33 While the role of circulating or vessel-derived EPCs is 
not completely understood, early studies suggested that these cells differentiate into 
mature ECs and contribute to capillary formation.33,34 However, more recent evidence 
suggests that EPCs also promote the proliferation, migration and survival of existing ECs 
and pericytes via paracrine mechanisms.35,36 
1.2.3 Arteriogenesis 
Under normal physiological conditions, pre-existing collateral arteries run parallel to the 
large conduit artery.26 Arteriogenesis is the process through which an obstruction of the 
conduit artery causes the remodeling and maturation of collateral vessels to increase 
perfusion in the distal tissues.37 Initially, elevation of the pressure gradient due to the 
vascular obstruction increases the rate of blood flow in the collateral vessels, which 
augments the fluid shear stress on the vessel walls.38 This mechano-stimulus alters the 
state of the endothelium, causing the activation of endothelial nitric oxide synthase 
(eNOS) and subsequent vasodilation of the collateral arterioles.38 Mechanical 
deformation of the ECs also enhances mechanoreceptor-dependent transcription of 
several adhesion molecules and chemokines, including monocyte chemoattractant 
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protein-1 (MCP-1), SDF-1 and GM-CSF.26,38 Attracted by these molecules, circulating 
monocytes migrate to the affected area, adhere to the endothelium, and migrate into the 
sub-endothelial space, where they differentiate into macrophages.26,32 In particular, a 
transformation towards the M2 macrophage phenotype has been shown to support 
collateral vessel formation through the production of supportive growth factors and 
cytokines, including VEGF, FGF, and HGF, as well as enzymes such as MMPs.39,40 The 
secreted molecules work in concert to cause rapid proliferation of the ECs and vascular 
SMCs required for collateral artery enlargement.26 Ultimately, arteriogenesis can result in 
the rapid enlargement of the collateral artery diameter up to 20× its original size in an 
effort to reduce vascular resistance and restore downstream perfusion.38 
1.3 Strategies for Revascularization of Ischemic Limb 
Alternative treatments are extremely limited for patients with diffuse PAD or CLI that do 
not qualify for surgical revascularization or endovascular procedures. In vivo 
compensatory responses to ischemic injury are compromised in patients with PAD, 
especially those involved with microvascular remodeling and maturation of collateral 
vessels.32 Moreover, the number of circulating EPCs are attenuated in these patients, 
likely due to the adverse effects of associated cardiovascular risk factors and co-
morbidities, such as hyperglycemia and hyperlipidemia.41 Therefore, intrinsic repair 
mechanisms become insufficient to overcome the burden of disease, demanding the need 
for new strategies to augment revascularization.  
As a result, the last 2 decades have seen extensive pre-clinical and clinical research into 
the development of new therapeutic interventions to promote vascular regeneration in 
patients with PAD. These approaches have primarily focused on the delivery of pro-
angiogenic growth factors through gene therapy approaches or controlled release 
strategies, and cell-based therapies to enhance blood flow to the ischemic regions. 
Although there has been some success in pre-clinical and clinical trials, several hurdles 
remain that limit efficacy and delay widespread use of these alternative therapies. 
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1.3.1 Gene Therapy Approaches for PAD 
The identification of pro-angiogenic growth factors in the 1980s, such as VEGF and 
FGF, led to their investigation in pre-clinical models of PAD to enhance angiogenesis 
and support functional improvement in ischemic limbs.26 Due to the short half-life 
(minutes) and pleiotropic effects of growth factors, a large number of pre-clinical and 
clinical trials have focused on utilizing gene therapy to provide a method for the 
sustained release of pro-regenerative factors.26 Gene transfer using plasmids or viral 
vectors, such as adenovirus or lentivirus, have served as a method for the localized or 
systemic delivery of specific pro-angiogenic factors to induce vascular regeneration in 
ischemic tissues.26  
In terms of pre-clinical testing, while other in vivo models are emerging, inducing murine 
hindlimb ischemia through the ligation of the superficial femoral artery is the most 
frequently used model of CLI to date.42 Using these models, gene therapy approaches 
have been utilized to stimulate angiogenesis and reperfusion by inducing the expression 
of various pro-angiogenic cytokines, including VEGF, FGF-2 and PDGF, and even the 
transcription factor HIF-1α.43–49 For example, intra-arterial delivery of adenovirus-
mediated gene transfer of VEGF in an ischemic hindlimb rat model improved perfusion 
and promoted the recovery of tissue oxygenation in the ischemic limb as compared to 
PBS controls over 4 weeks.44 Similarly, another study used a rabbit hindlimb ischemia 
model to demonstrate that repeated intramuscular injections of VEGF-encoding plasmids 
at day 7 and 21 post-surgery increased capillary density, arteriolar density and reduced 
muscle lesions as compared to the empty-plasmid control group over 50 days.45 Dual 
gene FGF-2/PDGF-BB plasmid administered intramuscularly into the ischemic hindlimb 
in rats also enhanced vessel density and limb perfusion as compared to the control 
plasmid group at 4 weeks.46 In addition, mediators of angiogenic function, such as eNOS, 
have also been studied in pre-clinical trials using gene therapy.49 For example, Brevetti et 
al. reported that adenovirus-mediated transfer of eNOS cDNA via intra-arterial 
administration in a rat hindlimb ischemia model increased the size and number of 
collateral arteries, enhanced muscle oxygen tension and augmented limb perfusion as 
compared to PBS or adenoviral vector controls at 14 days.49 
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While gene therapy has shown promise in pre-clinical models, clinical trials have 
generated mixed results. In two phase I trials, VEGF-encoding plasmids were injected 
intramuscularly into the limbs of CLI patients with severe ulcers and ischemic rest 
pain.50,51 Patients showed improvements in ankle brachial index (ABI; a ratio of blood 
pressures in the foot), improved distal flow, enhanced wound healing and attenuated rest 
pain at 4-8 weeks after treatment. However, several patients developed peripheral edema 
in both trials, corresponding temporarily to the rise in VEGF serum levels. In a phase 
I/IIa trial, HGF-encoding plasmid was administered intramuscularly in the calf or distal 
thigh of patients with PAD, and the treatment was repeated 4 weeks after the initial 
injection.52 A 2-month follow-up revealed that the patients had improved ABI, ulcer 
healing and pain relief without any side-effects. In a phase II clinical trial, the RAVE 
(Regional Angiogenesis with Vascular Endothelial Growth Factor) study assessed the 
effects of adenovirus encoding VEGF injected intramuscularly at a low- or high-dose in 
patients with IC.53 No differences in peak walking time, onset of claudication and quality-
of-life assessment were observed between the placebo and the low- or high-dosage 
treatment groups at 12 weeks. Similar trends were observed when a plasmid-expressing 
developmental endothelial locus-1 (Del-1) or an adenoviral construct encoding HIF-1α 
were administered intramuscularly in patients with IC, as the treatment and placebo 
groups showed similar improvements in peak walking time at 3 or 6 months.32,54,55 
Furthermore, intramuscular delivery of plasmid-based FGF-1 in CLI patients has also 
failed to significantly improve transcutaneous oxygen pressure (TcPO2) or healing of 
chronic ulcers as compared to the placebo group at 25 weeks.56 In general, large-scale 
clinical trials involving gene therapy have demonstrated limited improvements for 
patients with moderate to severe PAD. 
A postulated reasons for the poor translation of gene therapy in clinical trials may be the 
low DNA transmission efficiency at the targeted ischemic sites after treatment.26 In 
addition, vectors such as adenovirus and lentivirus employed in gene therapy may elicit a 
local and/or systemic inflammatory response.26 Another potential danger of gene-based 
therapy involves vector-mediated insertional mutagenesis, as observed in the Fischer 
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Trial where one patient developed lymphoproliferative disorder ~2.5 years after the 
retroviral-based treatment.57 
1.3.2 Cell-based Therapy Approaches for PAD 
With the growing understanding of the roles of progenitor and stem/stromal cells co-
ordinating concurrent post-ischemic angiogenesis, vasculogenesis and arteriogenesis 
processes, cell-based therapies have drawn attention as potential treatment options for 
patients with PAD.58–60 A variety of cell types have been studied in pre-clinical and 
clinical trials, including unselected mononuclear cells and marker-specific hematopoietic 
cells selected from bone marrow or peripheral blood. While early evidence suggested that 
these cells facilitated vascular regeneration by incorporating directly into the nascent 
blood vessels, recent studies have shown that the majority of transplanted cells are found 
adjacent to the newly-formed vasculature and provide paracrine signals to support 
vascular growth.61–63 As an illustration, Ziegelhoeffer et al. demonstrated via cell tracing 
of green fluorescent protein (GFP+)-labeled BM-derived mononuclear cells that 
intravenously delivered cells in a murine model of hindlimb ischemia failed to colocalize 
with the ECs or SMCs of the nascent vessels.64 Instead, GFP+ cells were localized in the 
perivascular space of collateral vessels, with a 3-fold higher expression as compared to 
the vessels in the non-ligated control limb. Multiple studies have supported the notion 
that transplanted hematopoietic progenitors or more mature cells of the 
monocyte/macrophage lineage primarily act as trophic mediators during angiogenesis, 
through the secretion of a broad array of growth factors and chemokines in a temporally 
and spatially controlled manner.63,65 Therefore, cell-based strategies may provide a 
suitable means for continuous delivery of pro-angiogenic factors over an extended period 
at the target site to facilitate vascular regeneration. 
1.3.2.1 Strategies Using Unselected Mononuclear Cells 
Mononuclear cells (MNCs), harvested from bone marrow (BM-MNCs) or peripheral 
blood (PB-MNCs), are comprised of a highly heterogeneous mix of both primitive 
progenitors and mature hematopoietic cells (90%), and a smaller component of non-
hematopoietic cells including rare EPCs and stromal cells.66,67 In pre-clinical testing, 
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intramuscular injection of autologous BM-MNCs enhanced collateral vessel and capillary 
density, and improved perfusion in a rabbit hindlimb ischemia model at 4 weeks as 
compared to the BM-fibroblast transplanted groups or saline-injected controls.68 The first 
randomized, controlled trial for the treatment of ischemic limbs using the MNC 
population was the TACT (Therapeutic Angiogenesis using Cell Transplantation) study, 
in which patients with severe limb ischemia received intramuscular injections of 
autologous BM-MNCs in the affected limb.69 The study reported improved rest pain, 
TcPO2, ABI and pain-free walking as compared to the saline-injected control group at 6 
months. A 2-year follow-up to the study added that patients injected with BM-MNC had 
improved walking time/distance and ulcer healing.70 Considering that cell collection from 
the blood offers faster recovery and eliminates the need for anesthesia as compared to 
multiple bone marrow aspirations, PB-MNCs have been investigated as a cell source for 
pro-regenerative therapy to treat ischemic limbs.32 For example, Ozturk et al. 
administered autologous PB-MNCs intramuscularly in the affected limbs of diabetic 
patients with CLI.71 At 12-weeks, patients demonstrated reduced pain and showed 
improvements in TcPO2, ABI, walking distance and ulcer healing as compared to the 
baseline and placebo group. 
1.3.2.2 Strategies Using Selected Mononuclear Cells 
The discovery of circulating EPCs by Asahara et al.30 showed that a subpopulation of 
MNCs, which can be isolated based on surface markers such as the progenitor marker 
CD34, represented a mixture of pro-angiogenic hematopoietic and endothelial cell 
lineages that were capable of homing to sites of ischemia to facilitate vascular repair.32,67 
In a pre-clinical study, ex vivo expanded human EPCs administered through an 
intracardiac injection in a murine hindlimb ischemia model enhanced capillary density 
and blood flow in the ischemic limb over 4 weeks as compared to mice injected with 
EPC-conditioned media.72 Clinical feasibility of granulocyte colony stimulating factor 
(G-CSF)-mobilized CD34+ cells for ischemic limb treatment was evaluated in a phase 
I/IIa trial, where cells were harvested by leukapheresis, purified for CD34-expression, 
and injected intramuscularly (3 doses: 105, 5×105, 106 cells/kg) into the more severely 
ischemic leg of patients with bilateral PAD.73 Although no dose-dependent relationship 
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was established after 12 weeks, the treated leg exhibited significant improvements in 
ulcer size, pain and walking distance as compared to baseline levels, and exhibited 
increased TcPO2 as compared to the untreated leg. Long-term clinical benefits of 
autologous G-CSF-mobilized CD34+ cells were also reported by Losordo et al. in the 
ACT-34 CLI (Autologous Cell Therapy-34 Critical Limb Ischemia) phase I/II study, 
where intramuscular administration of the cells within the ischemic lower limb of patients 
with moderate to severe CLI reduced the incidence of amputation in the cell-treated 
groups as compared to the control group at 12 months.74  
High aldehyde dehydrogenase (ALDH) activity has also been used as a marker to isolate 
pro-angiogenic cell populations within the heterogeneous mix of MNCs. ALDH is an 
oxidizing enzyme with high expression in primitive hematopoietic progenitors, and BM-
MNCs can be selected for high ALDH expression in the population that is CD34+, 
CD133+, CD13+ and CD117+.75,76 Pre-clinically, human BM-MNCs selected for high 
ALDH expression and administered in a murine hindlimb ischemia model through tail 
vein injection enhanced perfusion recovery and increased blood vessel density as 
compared to PBS-injected and unpurified MNC-treated groups over 21 days.77 A phase I 
controlled clinical trial compared the efficacy of unselected BM-MNCs and BM-MNCs 
selected for high ALDH activity by injecting autologous cells in the gastrocnemius 
muscle of the affected limb in patients with CLI.78 Although both groups demonstrated 
significant ABI improvements from baseline at 12 weeks, neither group showed 
significant improvement in ischemic ulcers or TcPO2. 
1.3.2.3 Current Limitations of Cell-based Therapeutic Approaches 
Although direct intramuscular administration of pro-regenerative cells at ischemic sites 
has shown some potential in stimulating new blood vessel growth, the application of cell-
based interventions in the clinical setting faces several limitations. First, the feasibility of 
cell-based therapies is dependent on the abundance and accessibility of the cell source. 
Depending on the cell types used, therapy is predicted to require at least 107 to 109 cells 
per patient.79 In terms of the cell type used, mononuclear cells are a highly heterogeneous 
cell population, with only a small fraction possessing pro-angiogenic capacity.80 For 
example, the low frequency (1-2%) of pro-angiogenic CD34+ hematopoietic progenitor 
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cells in the mononuclear cell population isolated from bone marrow or umbilical cord 
may require clinicians to obtain large sample volumes that may not be practical in all 
cases.69,79,81 Significant in vitro expansion of pro-regenerative cells needed for cell-based 
therapy may also contribute towards diminished cell function.82 In addition, autologous 
cells from patients with chronic diabetes and associated comorbidities have been shown 
to have impaired function and reduced survival, thus limiting their pro-angiogenic 
effects.83,84 
Another major roadblock for cell-therapy is the poor localization, retention and survival 
of transplanted cells in the targeted tissues.85,86 While current approaches stimulate 
angiogenesis by injecting cell suspensions either intra-arterially or directly into the 
ischemic tissue, the viability and desired function of transplanted cells at the targeted 
sites remains limited. As an illustration, Collins et al. reported that human BM-MSCs 
injected into the ischemic rat heart showed only 9% and 1% cell retention within the 
targeted tissue at 24 hours and 5 days post-transplantation, respectively.87 Poor retention 
may be explained by cell washout after direct injection, cell migration into the circulation 
and peripheral tissues, or cell death due to local hypoxic and inflammatory conditions.85  
While the clinical trials with cell-based therapy have been safe, well tolerated, and 
showed some beneficial effects, with the exception of the ACT-34 CLI trial, limb salvage 
rates were generally not reduced to clinically significant levels and the field still awaits a 
successful phase II – III study for CLI.32 As such, there is a critical need to select potent 
pro-angiogenic cell populations and design cell delivery modalities that improve cell 
survival, retention and paracrine function post-transplantation to better stimulate vascular 
regeneration and functional recovery in ischemic tissues. 
1.4 Mesenchymal Stem/Stromal Cells for Cell-based 
Angiogenic Therapies 
Mesenchymal stem/stromal cells (MSCs) are fibroblast-like plastic adherent cells that can 
be derived from a variety of tissues, including bone marrow, adipose tissue and skeletal 
muscle, and hold the potential to circumvent some of the practical limitations associated 
with cell-based therapies for PAD.88 MSCs are efficiently expanded in culture and retain 
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the capacity to differentiate into multiple different cell types associated with the 
mesodermal lineage, including adipocytes, osteocytes, chondrocytes and myocytes.89 
While the regulation of paracrine activity in MSCs is not completely understood, studies 
have shown that these cells migrate to sites of ischemic injury from their perivascular 
niche, and secrete bioactive factors that can stimulate angiogenesis, limit apoptosis, 
modulate inflammation, and enhance endogenous cell recruitment to the site of injury.90,91 
In addition, MSCs have been shown to be resilient to apoptosis under serum-starvation or 
hypoxic conditions, making them a promising source for cell-based therapies targeted for 
ischemic tissues.92 MSCs can be used for autologous or allogeneic therapeutic 
applications due to their ability to evade immune-surveillance resulting from the low 
expression of the major histocompatibility complex II antigen.93,94 In addition to their pro-
angiogenic paracrine capacity, MSCs demonstrate immuno-modulating effects at 
ischemic sites via the suppression of inflammatory cytokine production and by 
attenuating T-cell activation, proliferation, and migration.94  
Due to their pro-regenerative properties, MSCs have also been pursued as a potential 
candidate for cell-based therapies.95 In a pre-clinical trial, autologous BM-MSCs injected 
intramuscularly in a femoral artery ligation (FAL)-induced rabbit hindlimb ischemia 
model significantly increased limb perfusion and capillary/muscle fiber density in the 
treated limbs as compared to saline-injected control limbs at 28 days.96 Similarly, human 
placental-derived MSCs cultured under hypoxic conditions (2% O2) significantly 
improved microvessel density, blood perfusion and physiological status (limb salvage 
and foot necrosis) in the treated limb as compared to PBS controls over 28 days 
following intramuscular injection in a murine hindlimb ischemia model.97 
In a randomized controlled clinical trial, either BM-MNCs or BM-MSCs were injected 
intramuscularly into the lower limbs of diabetic patients with CLI.98 While both groups 
significantly improved pain-free walking time at 6 months as compared to saline injected 
controls, the BM-MSC treated group showed significantly greater collateral blood vessel 
scores and faster ulcer healing time (8 vs. 12 weeks) relative to the BM-MNC group, 
suggesting the potential benefits of MSCs over unselected BM-MNCs. More recently, 
human BM-MSCs isolated from healthy donors were expanded in vitro and injected into 
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the gastrocnemius muscle of the ischemic lower limb of patients with CLI.99 At 24 
weeks, patients demonstrated significantly higher ABI and reduced pain as compared to 
baseline levels and the placebo group. Given these positive outcomes, MSCs provide a 
clinically-applicable pro-regenerative cell population for future cell-based therapy. 
1.4.1 Adipose-derived Stem/Stromal Cells (ASCs) 
Adipose-derived stem/stromal cells (ASCs) have gained interest as an attractive MSC 
cell-type for regenerative therapies due to their relative abundance, accessibility, and 
secretory functions.93,100 ASCs are derived from adipose tissue and have promising 
characteristics for applications in therapeutic angiogenesis.93 ASCs actively secrete 
multiple pro-angiogenic factors and cytokines, including VEGF, FGF-2, HGF, PDGF and 
TGF-β, that are involved in the process of vascular regeneration.101 ASCs can also be 
readily expanded in culture, and have been shown to establish a regenerative milieu in 
vivo through paracrine mechanisms.93,102–104  
In addition to their pro-angiogenic stimulatory potential, ASCs offer practical advantages 
for their clinical applicability in cell-based therapies. Although MSCs can be sourced 
from the patient’s own bone marrow, the retrieval process is invasive, painful and may 
not be ideal for individuals with adverse vascular conditions such as CLI. In contrast, 
adipose tissue can be harvested via minimally-invasive liposuction techniques under local 
anesthesia, with minor morbidity.93 In addition, compared to the MSC frequency of 
1:50,000–1:1,000,000 in bone marrow, ASC frequency in human adipose tissue ranges 
between 1:30–1:100 per total nucleated cells, and therefore requires less tissue to 
generate significant numbers of ASCs for cell-based therapies.85,100,105,106 Furthermore, a 
limited volume of bone marrow can be safely harvested from each donor, which could 
necessitate significant in vitro expansion of BM-MSCs for cell-based therapies. Adipose 
tissue however, offers a source of MSCs in high abundance with large proliferative 
potential, thereby enhancing the feasibility of safely harvesting the required volumes of 
adipose tissue and minimizing culture times for ex vivo expansion.79,88  
In pre-clinical testing, intramuscular injection of human ASCs into the ischemic limb of  
nude mice with FAL-induced hindlimb ischemia significantly enhanced vascular density 
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and blood flow in the treated limb as compared to the saline-injected control limb at 14 
days.107 Similarly, ASCs isolated from murine inguinal fat pads and transplanted 
intramuscularly into the ischemic hindlimb of mice enhanced capillary density within the 
thigh adductor muscles and improved blood flow as compared to saline-injected controls 
at 4 weeks.108 The first phase I clinical trial utilizing autologous MSCs isolated from 
abdominal fat of CLI patients, ACellDream (Adipose Cell Derived Endothelial 
Regenerative Endothelial Angiogenic Medicine), demonstrated that intramuscular 
administration of the cells in the ischemic limb improved rest pain, TcPO2 and wound-
healing response at 24 weeks.109 Intramuscular administration of autologous adipose-
derived MSCs around the edges of chronic ulcers in PAD patients significantly reduced 
the depth and diameter of the wounds over 90 days, while also reducing the wound-
associated pain.110 Therefore, ASCs have demonstrated pro-regenerative potential in cell-
based therapies. 
1.4.2 Immunophenotype of ASCs 
The primary stromal vascular fraction (SVF) isolated after adipose tissue digestion 
consists of a heterogeneous cell population, including ASCs, vascular endothelial and 
smooth muscle cells, pre-adipocytes, fibroblasts, erythroblasts, pericytes and 
hematopoietic cells.111 This heterogeneity is reduced by using expansion conditions that 
select for plastic-adherent stromal cells. ASC characterization has been defined under the 
guidelines of the International Society for Cellular Therapy (ISCT) and the International 
Federation for Adipose Therapeutics and Science (IFATS).112 To adhere to the ASC 
characterization criteria, ASCs must: (1) maintain plastic adherence in cell culture, (2) 
express a standardized immunophenotypic profile, and (3) maintain tri-lineage 
differentiation capacity along the adipogenic, osteogenic, and chondrogenic lineages.  
According to the ISCT and IFATS, ASCs must show >80% expression of defined 
stromal cell markers (CD90, CD44, CD29, CD73 and CD105) and <2% expression of 
hematopoietic (CD45) and endothelial (CD31) cell specific markers.112 ASCs have been 
shown to express a fairly robust immunophenotypic profile as summarized in Table 
1.2.93,112–114 As demonstrated by Mitchell et al., successive passaging of ASCs may alter 
expression of certain cell surface markers.100 For example, while the surface marker 
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expression of CD34 and CD146 were ~60% and 21% in the initial SVF, the expression of 
each marker declined to ~2% by passage 3 for human ASCs.100 
Table 1.2. Immunophenotypic profile of ASCs.93,112–114 
Marker type Category Antigen 
Positive 
(>80%) 
Adhesion 
molecules 
CD29 (integrin β1) 
CD105 (endoglin) 
CD50 (intercellular adhesion molecule 1) 
CD54 (intercellular adhesion molecule 3) 
CD166 (activated lymphocyte cell adhesion 
molecule) 
Receptor molecules CD44 (hyaluronic acid receptor) 
CD71 (transferrin receptor) 
Surface enzymes CD73 (ecto 5’nucleotidase) 
CD13 (aminopeptidase) 
CD10 (neutral endopeptidase) 
Surface 
glycoproteins 
CD90 (Thy-1) 
CD147 (neurothelin) 
CD146 (melanoma cell adhesion molecule)* 
CD34 (progenitor associated marker)* 
Negative 
(<2%) 
Adhesion 
molecules 
CD31 (platelet endothelial cell adhesion 
molecule) 
CD106 (vascular cell adhesion molecule) 
Receptor molecules CD45 (leukocyte common antigen) 
CD3 (T-cell co-receptor) 
Surface 
glycoprotein 
CD133 (hematopoietic and endothelial 
progenitor marker) 
*Variable levels of expression.100 
1.4.3 Influence of Hypoxia on ASCs 
As PAD progresses, the lack of oxygenated blood flow to the distal limb creates a 
hypoxic microenvironment, resulting in cell apoptosis and subsequent necrosis of the 
affected tissues.115 A TcPO2 of <20 mm Hg (<2% O2) in the lower extremity is correlated 
with impaired healing, requiring patients to undergo revascularization procedures or 
amputation to treat the severe conditions.115 Therefore, the efficacy of cell-based therapy 
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for PAD relies on the transplanted cells being able to survive and function in 
microenvironments with low oxygen tension.  
Under hypoxic conditions, ASCs have been shown to upregulate expression of several 
pro-angiogenic genes, including VEGF, FGF-2, HGF, Ang-1, PDGF and SDF-1, and 
cytokines such as interleukin-10 (IL10) and interleukin-8 (IL-8).116–118 The elevated 
expression of these pro-angiogenic molecules is achieved through the activity of HIF-1α 
under low oxygen tension (<5% O2).119–121 One study showed that the conditioned 
medium obtained from human ASCs cultured under hypoxic conditions (1% O2) can 
improve endothelial cell growth and reduce apoptosis.122 In addition, hypoxic pre-
conditioning of human ASCs enhances their ability to bind to vascular cell adhesion 
molecule-1 (VCAM-1) and endothelial intercellular adhesion molecule-1 (ICAM-1), 
suggesting the potential for augmented attachment to endothelial cells in ischemic 
regions.123 Hypoxic conditions (1% O2) have also been shown to enhance human ASC 
proliferation in vitro by >1.5-fold as compared to ASCs cultured under 20% O2 over 7 
days.124 Collectively, ASCs are generally resilient to hypoxic conditions in terms of 
survival and function, thus providing support for their use in cell-based therapies to 
promote angiogenesis at ischemic sites. 
1.5 Biomaterials for Scaffold-based Cell Delivery 
As discussed earlier, poor retention and survival of transplanted cells are major 
limitations identified in previous studies of cell-based therapies for PAD.85,125,126 As a 
result, scaffold-based cell delivery strategy has emerged to circumvent cell loss by 
providing anchorage for the transplanted cells while promoting cell viability and function 
at ischemic sites.127 Scaffolds can be developed to have similar porosity and 
nanostructure as the native ECM to support in vivo engraftment, and can also be modified 
with cell-signaling moieties to facilitate cell-cell and cell-ECM interactions.127 Therefore, 
in-depth analysis of biomaterial design is required to develop promising scaffolds for 
cell-based therapy. 
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1.5.1 Scaffold Design Requirements 
Designing a cell-delivery scaffold for enhancing transplanted ASC survival within the 
context of PAD requires careful consideration of material requirements. Ideally, the 
scaffold should retain viable cells at the target site over the course of tissue regeneration. 
In addition, the scaffold should provide anchorage for encapsulated cells to support cell 
function by promoting the sustained delivery of pro-regenerative paracrine factors into 
the ischemic region.85 To facilitate the intended role of ASCs as trophic mediators, the 
scaffold must allow for easy diffusion of nutrients and factors between encapsulated 
ASCs and the surrounding microenvironment.128 Furthermore, the mechanical properties 
of the scaffold should align with those of the surrounding tissues at the target site to 
minimize physical irritation, prevent inflammation and facilitate integration of the 
scaffold after delivery.129 For instance, the Young’s modulus of the medial gastrocnemius 
in the limb of resting human subjects is ~16 kPa.130 Accordingly, a scaffold with similar 
mechanical properties would promote better integration within the target muscle in 
patients with PAD. In addition, the scaffold should be pliable, durable, and able to resist 
repeated mechanical deformation during muscle contractions with minimal risk of 
fracture.129 Lastly, the transplanted scaffold should also undergo biodegradation at a slow 
rate to retain the transplanted cells during the course of the therapy, and break down in a 
manner that does not interfere with ongoing vascular remodeling processes.16  
In general, two methods of scaffold delivery have been investigated in the context of pro-
angiogenic cell therapies. One option is the surgical implantation of cell-seeded pre-
formed scaffolds. Although pre-formed scaffolds allow for greater control over scaffold 
shape, this approach requires invasive surgical techniques for implantation at target 
sites.85 A less invasive approach is to deliver a bolus of cells suspended in an aqueous 
polymer precursor solution (pre-polymer) as an injectable substrate that subsequently 
cross-links in situ to form a robust hydrogel scaffold, effectively encapsulating the 
delivered cells.16,85 Injectable delivery offers several advantages for PAD treatment 
including minimally-invasive cell delivery using a small gauze needle, shorter procedure 
time, and minimal damage to the already compromised ischemic region.85 Due to these 
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benefits, our collaborative team has focused on investigating the use of cross-linkable 
polymers as an in situ-gelling cell delivery scaffold. 
1.5.1.1 Hydrogels 
Hydrogels are water-swollen polymer networks that are physically or chemically cross-
linked.16 They can be prepared from biocompatible and biodegradable polymers that 
provide a supportive microenvironment for cell-delivery applications.131 Since hydrogels 
are inherently well hydrated, they allow for easy diffusion of gasses, nutrients, metabolic 
products and bioactive molecules from within the scaffold to the surrounding tissues.131 
Additionally, the mechanical properties of the hydrogel can be controlled through cross-
linking density, electrostatic interactions of the polymer chains, and the degree of 
swelling to tailor their use towards the in vivo environment of the target tissue.16 
Generally, the pre-polymer solution is combined with the cells of interest in an aqueous 
medium and injected into the target site, where it subsequently cross-links to form a 
scaffold in situ.  
Several natural and synthetic polymers have been investigated as cell delivery vehicles. 
Scaffolds comprised of synthetic polymers, including poly(ethylene glycol), poly(lactic 
acid), poly(N-isopropylacrylamide) and poly(vinyl alcohol), offer several advantages 
such as batch-to-batch consistency, amenability to chemical functionalization, and 
precise control over mechanical and degradation properties.85 However, they lack the 
innate bioactivity of natural materials that can better support cell adhesion, viability, 
migration, and differentiation.85,132 Furthermore, acidic degradation products of synthetic 
polymers such as poly(lactic acid) can be cytotoxic and may trigger inflammatory 
responses.133,134 Concerns regarding in vivo excretion also exist with synthetic scaffolds. 
For example, poly(N-isopropylacrylamide) may accumulate in the liver and spleen to a 
significant extent within 48 h of intravenous administration, regardless of its molecular 
weight.135 To circumvent the limitations of synthetic materials, several major classes of 
naturally-derived or semi-synthetic polymers have been studied within the context of 
ischemic conditions, as described in detail in section 1.5.2. 
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1.5.1.2 Cross-linking Strategy 
An injectable cell-delivery scaffold requires a cross-linking mechanism that allows for 
cell loading in the aqueous phase, but then forms a cell-encapsulated matrix following 
injection. An efficient mechanism should initiate gelation in a triggered or controlled 
fashion in order to prevent premature or delayed cross-linking, and the cross-linking 
should not initiate an immunogenic response.85 Most importantly, the cross-linking 
mechanism should be cytocompatible to encapsulated cells, as well as the surrounding 
host tissues.85  
Although several physical and chemical methods have been investigated to facilitate 
cross-linking of hydrogel polymer networks, there are a limited number of clinically-
applicable cross-linking strategies appropriate for cell encapsulation. For instance, 
glutaraldehyde cross-linking of hydroxylated polymers requires methanol, low pH and 
high temperatures.136,137 These conditions, along with the inherent reactivity of 
glutaraldehyde to amines, amides and thiol groups in proteins, would render this 
approach cytotoxic for the encapsulated cells and could further damage the ischemic 
tissues.138  
Hydrophilic polymers including hyaluronic acid (HA), chitosan, and chondroitin sulfate 
can be modified to undergo chemical cross-linking via radically-initiated methacrylate or 
acrylate polymerization.129,139 The methacrylate and acrylate groups contain highly 
reactive double bonds that propagate cross-linking through free-radical 
polymerization.140,141 This cross-linking approach can offer flexibility in terms of the pH, 
osmolarity, and temperature conditions, and may present an attractive strategy for in situ 
gelation of polymer scaffolds. For instance, low-intensity UV cross-linking of 
methacrylated glycol chitosan in the presence of the photo-initiator Irgacure 2959 has 
been shown to generate hydrogels with high cross-linking efficiency.140 Although UV 
cross-linking of methacrylated polymers is effective in vitro, direct access of a UV light 
at the site of delivery increases invasiveness of implantation and limits clinical 
applicability. Alternatively, a chemical initiator to catalyze free-radical polymerization 
using ammonium persulfate (APS) and the accelerator N,N,N’N’-
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tetramethylethylenediamine (TEMED) offers an attractive cross-linking approach. This 
system of redox initiators generates free radical species, which subsequently facilitate 
methacrylate cross-linking at 37ºC.142,143 The efficacy of this thermally-sensitive cross-
linking approach has been previously shown in vitro and in vivo.129,144 For example, one 
study used 25 mM APS/TEMED to encapsulate rat BM-MSCs in diacrylate-modified 
oligo[poly(ethelene glycol) fumarate] hydrogels at 37ºC.144 Over a 28-day culture period, 
the encapsulated cells were able to maintain viability and differentiate in the presence of 
osteogenic supplements. Therefore, APS/TEMED-facilitated free-radical polymerization 
of methacrylate- or acrylate-functionalized scaffolds offers a promising cross-linking 
strategy for in situ gelation and cell encapsulation. 
1.5.1.3 Cell-adhesive Peptide Ligand Functionalization 
With increasing understanding of the important roles of cell-ECM interactions in 
mediating cell function, there is great interest in the development of novel biomaterials 
that mimic the native tissue microenvironment. While cross-linking allows for the 
manipulation of the mechanical properties of the scaffolds, biomaterials can be 
functionalized with bioactive moieties to further direct cell function. Some studies have 
explored the incorporation of full-length ECM proteins such as collagen, fibronectin, 
vitronectin and laminin. Alternatively, polymers can be modified with small bioactive 
peptide ligands derived from these common ECM proteins, such as the integrin-binding 
RGD, IKVAV or YIGSR sequences.145,146 
These ECM-derived peptide ligands bind to integrins—a diverse class of α/β 
heterodimeric transmembrane cell-adhesion receptors (Figure 1.1).147 While each α/β-
heterodimer has its own ligand binding specificity, many integrins bind more than one 
peptide ligand.148,149 Integrin-mediated binding of cells with ECM-derived peptide 
ligands has been shown to mediate a variety of cell responses including attachment, 
growth and motility.150–152 Although the specific mechanisms are still being elucidated, 
integrin engagement facilitates transduction pathways through phosphorylation of 
intracellular proteins and second messenger signaling to promote cell adhesion, survival, 
proliferation and migration (Figure 1.1).153,154 Individual cells can also vary their 
adhesive and migratory properties by selective expression of integrins with varying α/β 
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subunit composition.149 Importantly, cells detached from their ECM have been shown to 
undergo apoptosis in an integrin-mediated pattern known as anoikis.155 As an illustration, 
fibronectin or vitronectin binding via integrins α5β1 and αvβ3 in hamster ovary cells 
decreased the activity of apoptosis-inducing caspase-3 protein, and enhanced the 
expression of B-cell lymphoma-2 (Bcl-2), a regulatory protein that inhibits apoptosis.156 
In general, the functionalization of scaffolds with integrin-binding cell-adhesive peptides 
is of interest in the field to promote long-term cell survival, retention and support pro-
regenerative cell functions. 
 
Figure 1.1. Schematic representation of integrin structure. Integrins are heterodimeric receptors 
consisting of non-covalently bound α and β subunits. Both α and β subunits have an extracellular 
domain that binds to peptide ligands (e.g. RGD, IKVAV, etc.), and a short cytoplasmic tail that 
interacts with cytoskeletal elements. Integrin engagement facilitates downstream intracellular 
signaling, influencing various transduction pathways and mediating multiple cell functions. Image 
adapted from Millard et al.157 FAK: focal adhesion kinase; PI3K: phosphoinositide 3-kinase; Akt: 
protein kinase B; MAPK: mitogen-activated protein kinase; ERK: extracellular signal-regulated 
kinase. 
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1.5.1.3.1 Arginine-Glycine-Aspartic Acid (RGD) Motif 
The tri-peptide arginine-glycine-aspartic acid motif, or RGD, is an integrin-binding 
sequence derived from fibronectin and collagen.158 RGD is a well characterized adhesion 
motif that was originally shown to facilitate binding through the α1β1 complex.158 
Currently, as many as 12 out of the 20 known integrins have been shown to recognize the 
RGD sequence, including αvβ3 and α5β1.158 Since RGD is found in many cell adhesion 
proteins, it has been used to promote cell attachment to various biomaterials and can be 
recognized by many cell types, including MSCs.159–161 For example, rat BM-MSCs 
seeded within RGD-modified oligo[poly(ethylene glycol) fumarate] hydrogels have 
demonstrated improved cell adhesion and spreading.162 More recently, mouse BM-MSCs 
encapsulated within HA hydrogels demonstrated enhanced cell attachment, spreading and 
β1 integrin expression in a dose-dependent manner when presented with RGD motifs.163 
In a comparative study, RGD-modified poly(ethylene glycol) (PEG) hydrogels 
demonstrated improved viability of seeded human BM-MSCs as compared to unmodified 
controls over 7 days, while this effect was less pronounced in IKVAV-modified 
hydrogels.164 
1.5.1.3.2 Isoleucine-Lysine-Valine-Alanine-Valine (IKVAV) Motif 
Laminin is a basement membrane glycoprotein with diverse biological roles.165 The 
isoleucine-lysine-valine-alanine-valine motif, or IKVAV, derived from the laminin-α1 
chain has been suggested as the sequence that facilitates cell adhesion, spreading and 
outgrowth.165 Interestingly, rat pre-adipocytes demonstrated enhanced α1β1-mediated 
adherence on laminin-1 treated ECM substrates as compared to fibronectin and collagen 
treated groups.166  Immobilization of IKVAV motifs on collagen type I hydrogels has 
also been shown to stimulate migration, adhesion, and capillary network formation in 
vascular endothelial cells.167 Further, human neural stem cells encapsulated within silk 
fibroin-based hydrogels covalently modified with IKVAV peptides enhanced cell 
viability and differentiation capacity relative to non-peptide modified controls.168 In 
addition, supplementation of IKVAV peptide in cell culture media has been shown to 
induce proliferation of human BM-MSCs in a dose-dependent manner, mediated through 
the activation of the extracellular signal-regulated kinase 1/2 (ERK1/2) and protein 
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kinase B (Akt) signaling pathways, and through augmented cell cycle progression into S 
phase.169 Taken together, the pro-survival effects of the integrin-binding RGD and 
IKVAV peptide ligands have been well documented, providing a rationale for 
incorporating these motifs within cell-delivery scaffolds. 
1.5.2 Polymers for Hydrogel Scaffold 
1.5.2.1 Chitosan 
Chitosan is the deacetylated form of the linear polysaccharide chitin—a component of 
crustacean exoskeletons—and consists of random (1-4)-linked β-D-glucosamine and N-
acetyl-D-glucosamine monomers (Figure 1.2A).85 Chitosan is an attractive material for 
cell-delivery applications due to its cytocompatible, biodegradable, hemostatic, 
antimicrobial and wound healing properties.170–172 Chitosan has also been suggested to 
induce neovascularization in ischemic tissues due to its innate pro-angiogenic nature.173,174 
The electrostatic interactions of chitosan with glycosaminoglycans (GAGs), 
proteoglycans and other negatively charged species in the body have the potential benefit 
of sequestering pro-regenerative growth factors and facilitating scaffold integration with 
the native tissues.175 Chitosan can undergo degradation in vivo through the action of 
lysozymes via hydrolysis, generating biocompatible oligosaccharides and 
glucosamines.170,176 In addition, components of chitosan have been shown to improve cell 
viability by protecting the cells from reactive oxygen species (ROS), such as H2O2, 
generated in the ischemic tissues.174 In addition, chitosan-based hydrogels have been 
previously explored to promote cell retention in vivo. For example, a temperature-
sensitive chitosan hydrogel was used to encapsulate and deliver rat ASCs in a rat MI 
model.174 The findings indicated that a higher retention of transplanted cells was noted 
with hydrogel-based cell delivery as compared to PBS controls over 28 days. 
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Figure 1.2. Chemical structure of chitosan and its derivatives. (A) Chitosan, composed of 
(1-4)-linked β-D-glucosamine and N-acetyl-D-glucosamine monomers, (B) glycol chitosan, and (C) 
N-methacrylate glycol chitosan. Images adapted form Russo et al.85 
Although chitosan demonstrates limited solubility in aqueous environments at 
physiological pH, its glycosylated form known as glycol chitosan (GC) (Figure 1.2B) is 
soluble between pH 2-12.177 Furthermore, GC can be functionalized with methacrylate 
groups via a ring opening reaction with glycidyl methacrylate (GMA) to form N-
methacrylate glycol chitosan (MGC) (Figure 1.2C).140 To initiate cell encapsulation, the 
MGC pre-polymer and cell suspension can be mixed with APS and TEMED at room 
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temperature. Although the formation of radical species begins immediately, the slow rate 
of this reaction at room temperature allows for easy handling of the material. Upon 
injection or incubation at 37ºC, the elevated temperature increases the rate of the initiator 
decomposition and free-radical formation. The increased molecular kinetics at higher 
temperatures also enhances the mobility of the polymer chains, resulting in cross-linking 
of the methacrylate groups and rapid gelation of the MGC to facilitate cell 
encapsulation.129,144,178 Therefore, the pro-regenerative and cytocompatible nature of 
chitosan, combined with the practical advantages offered by the MGC polymer, lend 
support for its use as a bioscaffold in cell-based delivery, as investigated in this thesis. 
1.5.2.2 Alginate 
Derived from brown seaweed and algae, alginate is a natural anionic polysaccharide 
composed of (1-4)-linked β-D-mannuronic acid (M unit) and α-L-guluronic acid (G 
unit).85 Addition of divalent cations such as Ca2+ and Ba2+ causes the G unit blocks on 
adjacent chains to bind and form an ionic cross-linked network.85 Silva et al. 
demonstrated that the combination of VEGF and human umbilical cord blood-derived 
EPCs pre-seeded on implantable peptide-modified alginate scaffolds was able to improve 
vessel density, restore perfusion and salvage ischemic limbs in a murine model of 
hindlimb ischemia.179 In addition, alginate has been studied as an injectable cell delivery 
vehicle in pre-clinical models of MI, where the increased post-MI concentration of 
calcium ions facilitates the physical cross-linking process.180,181 As such, the gelation and 
degradation of alginate hydrogels is dependent on the local cation concentration in 
ischemic tissues and ion efflux into the surrounding tissues, respectively. This leads to an 
uncontrolled cross-linking approach, with degradation products being eliminated by the 
kidneys if below the excretion limit of 48 kg/mol.182 Furthermore, the hydrophilic nature 
of alginate necessitates grafting of cell-adhesive peptide ligands to promote encapsulated 
cell viability, as the unmodified scaffold limits protein adsorption and cellular 
attachment.183 
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1.5.2.3 Collagen 
Being a key component in the ECM, type I collagen derived from bovine or porcine 
tissues has been studied as a natural scaffold.85 It is also commercially-available and can 
be prepared as an injectable hydrogel by acid-solubilization.184 Collagen can undergo 
entropy-driven self-assembly through fibriollogenesis to form a physically cross-linked 
hydrogel capable of encapsulating cells upon in vivo injection at neutral pH and 
37ºC.184,185 Although collagen-based hydrogels support cell encapsulation and attachment, 
the solubilization process causes the hydrogel to lack elements of structural integrity and 
organization, including stiffness and elasticity.186 Furthermore, the cross-linking process 
is sensitive to in situ variations of pH and salt concentration, resulting in poor control 
over gelation and degradation of the scaffold.186 Delivery of radio-labeled MSCs via 
collagen hydrogels in a pre-clinical rat model of MI demonstrated that the hydrogel 
transiently improved MSC retention as compared to saline-delivered cells at 4 weeks.187 
However, the scaffold attenuated long-term survival of encapsulated MSCs by impairing 
oxygen and nutrient exchange.  
1.5.2.4 Fibrin 
Fibrin is a fibrous, non-globular protein that is involved in the coagulation cascades, and 
thus contains intrinsic sites for cell binding.85 Fibrin hydrogels are formed when 
fibrinogen is cleaved by thrombin, resulting in the rapid aggregation of the insoluble 
fibrin peptides that creates a fibril network capable of encapsulating cells.188 Due to the 
cross-linking nature of fibrin, the physical properties of the hydrogels, including gelation 
kinetics, stiffness and elastic moduli, can be tailored by altering the concentrations of 
thrombin and fibrinogen.189 Enzymatic degradation of fibrin produces non-
immmunogenic amino acid products that may also contribute towards angiogenesis.190 
Fibrin has been previously used as a delivery vehicle for MSCs or growth factors in pre-
clinical models of ischemia, and has been shown to promote functional repair in rat MI 
models over PBS controls.191 However, fibrin hydrogels have demonstrated poor 
mechanical properties in situ.192,193 Furthermore, commercially-available fibrin glues have 
failed to show improvement in long-term cell retention and function after injection.194  
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1.5.2.5 Hyaluronic Acid 
Hyaluronic acid, or HA, is a linear glycosaminoglycan composed of repeating 
disaccharide units of (1-4)-linked β-D-glucuronic acid and (1-3)-linked β-N-acetyl-D-
glucosamine.85 As a widely distributed component of the ECM in mammalian tissues, HA 
is involved in cellular proliferation and differentiation, and has been shown to have pro-
angiogenic effects.195 In a pre-clinical model of murine hindlimb ischemia, delivery of 
human umbilical vein endothelial cells (HUVECs) in combination with injectable HA 
resulted in prolonged cell retention, survival and cellular engraftment into the 
endothelium.196 HA can also be modified to produce a cross-linkable methacrylated HA 
(MeHA) that can undergo free-radical mediated polymerization to form a hydrogel.129 
Cell-free delivery of MeHA hydrogels has demonstrated potential in promoting the 
remodeling of ischemic tissues in a pre-clinical ovine MI model.139 However, the long-
term potential of HA as a cell-delivery scaffold is hindered by its rapid enzymatic 
degradation in vivo, with unmodified HA degrading into glucuronic acid and N-
acetylglucosamine at a rate of 5 g/day.197 
1.5.2.6 Matrigel™ 
Generated by murine tumor cells, Matrigel™ is a commercially-available material 
composed of laminin, entactin, collagen IV and other ECM components.85 Previous pre-
clinical research with a rat MI model demonstrated that the delivery of human embryonic 
stem cells (ESC)-derived cardiomyocytes in a Matrigel™ scaffold at ischemic sites 
resulted in poor cell viability and retention.198 When the study was repeated with a 
combination of cells and pro-survival growth factors delivered via the Matrigel™ 
scaffold, the comprehensive approach led to augmented cell survival and cell retention at 
the targeted ischemic site at 4 weeks.198 Despite these promising results, the xenogenic 
and tumorogenic origins of Matrigel™ prohibits its widespread translation in clinical 
applications.199 
1.6 Summary 
The rising incidence and limited treatment options for PAD motivate the need for new 
minimally-invasive treatment approaches to help stimulate new blood vessel formation 
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and tissue regeneration.1 Using an integrative approach combining cell-based therapy 
with scaffold-based delivery may improve angiogenesis inducing therapies for PAD and 
CLI. ASCs isolated from human adipose tissue offer a promising source for cell-based 
therapy due to their accessibility, high proliferative capacity, and paracrine function that 
stimulates pro-angiogenic responses and modulates inflammation.93,102–104 To address the 
poor survival and retention of transplanted cells, ASCs will be delivered in a thermally-
sensitive MGC pre-polymer that cross-links into a hydrogel through free radical 
polymerization using an APS/TEMED initiator system.142,143 To promote ASC adhesion 
and retention within the hydrogel, MGC will be functionalized with integrin-binding 
peptide ligands, including RGD found in fibronectin and collagen, or IKVAV derived 
from the laminin-α1 chain.145,165 The overarching goals of this thesis were to: (i) assess 
the viability and pro-angiogenic capacity of human ASCs encapsulated in the MGC 
hydrogels through in vitro and in vivo studies, and (ii) examine the effects of modifying 
the MGC with cell-adhesive RGD or IKVAV motifs on encapsulated cell function. 
Overall, this project aims to provide fundamental insight into the angiogenic function of 
human ASCs within 3-D engineered cellular microenvironments, and represents a critical 
next step in the rational design of a cell delivery vehicle for therapeutic angiogenesis. 
1.6.1 Hypotheses 
The underlying hypotheses for this project were that in situ cross-linking MGC hydrogels 
would provide a cell-supportive platform to facilitate human ASC encapsulation and 
retention with high cell viability, and that modification of the MGC with peptides 
incorporating the integrin-binding RGD or IKVAV sequences would modulate the 
angiogenic potential of the delivered ASCs. 
1.6.2 Specific Aims 
The specific aims of this Master’s project were: 
1) To assess the viability of human ASCs encapsulated within (i) MGC, (ii) MGC-
RGD, and (iii) MGC-IKVAV hydrogels cultured under simulated hypoxic 
conditions (2% O2) for up to 14 days. 
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2) To assess the expression of angiogenesis-associated genes in human ASCs 
encapsulated within (i) MGC, (ii) MGC-RGD, or (iii) MGC-IKVAV hydrogels 
and cultured for 7 days under simulated hypoxic conditions (2% O2) relative to 2-
D tissue culture polystyrene (TCPS) controls. 
3) To assess in vivo human ASC retention and markers of angiogenesis in the (i) 
MGC, (ii) MGC-RGD, or (iii) MGC-IKVAV hydrogels at 14 days following 
subcutaneous implantation in immunocompromised NOD/SCID mice. 
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Chapter 2  
2 MATERIALS AND METHODS 
Unless otherwise specified, all chemical reagents used in this project were purchased 
from Sigma-Aldrich Canada Ltd. (Oakville, ON). 
2.1 N-Methacrylate Glycol Chitosan (MGC) Hydrogel 
2.1.1 MGC Synthesis and Peptide Functionalization 
The N-methacrylate glycol chitosan (MGC) was prepared by Stuart Young (PhD 
Candidate) in Dr. Brian Amsden’s Lab at Queen’s University following published 
protocols.140,141,200 
Preparation of MGC: Glycol chitosan (GC, 85% degree of deacetylation; Wako 
Chemicals Inc., Virginia, USA) was dissolved in deionized water at 1% (w/v) and filtered 
to remove insoluble impurities. The solution was dialyzed using 50 kDa molecular 
weight cutoff membrane against distilled water, and then lyophilized to obtain purified 
GC. The purified GC was dissolved at 2% w/v in a 0.2 M sodium phosphate buffer at pH 
9, and reacted with either a 0.15 or 0.22 molar ratio of glycidyl methacrylate (GMA) to 
free amine of GC. The reaction was neutralized with 1.0 M hydrochloric acid, and the 
solution was dialyzed using a 12-14 kDa molecular weight cutoff membrane against 
distilled water. The resulting MGC solution was lyophilized, yielding a white crystalline 
powder.140 The degree of N-methacrylate substitution (DOS) was defined as the number 
of grafted methacrylate groups per 100 residues. 
Functionalization of MGC with an RGD-containing peptide: The GGGGRGDS peptide 
(RGD, 94% purity; CanPeptide Inc., Pointe-Claire, QC) peptide was dissolved at 
2% (w/v) in 0.15 M sodium phosphate buffer at pH 5.5. Next, 2.3 molar equivalents of N-
acryloxysuccinimide were dissolved in dimethylformamide and added dropwise, 
accounting for 10% of the final reaction volume. The reaction was stirred at 4°C, then 
diluted by half with distilled water and dialyzed using a 500 Da molecular weight cutoff 
membrane against distilled water. The purified solution was lyophilized to obtain N-
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terminal acrylated GGGGRGDS (Acr-RGD). MGC with a 5% degree of methacrylation 
was dissolved at 0.5% (w/v) in a 0.2 M sodium phosphate buffer at pH 8.5. The Acr-
RGD was added at a rate of 0.0625 mole per mole of MGC residue, and the solution was 
stirred at 37°C. The solution was then dialyzed using a 6-8 kDa molecular weight cutoff 
membrane against 0.2 M sodium chloride, and then against distilled water. The purified 
solution was lyophilized to obtain MGC functionalized with the GGGGRGDS peptide 
(MGC-RGD).141 
Functionalization of MGC with an IKVAV-containing peptide: MGC with a 7% degree 
of methacrylation was dissolved at 0.5% (w/v) in a 0.2 M sodium phosphate buffer at pH 
8.5. The CSRARKQAASIKVAVSADR peptide (IKVAV, 93% purity; CanPeptide Inc., 
Pointe-Claire, QC) was added at a rate of 0.05 mole per mole of MGC residue. A 2-fold 
molar equivalent of N-hexylamine was added, and the reaction was stirred at 37°C. The 
solution was dialyzed as described for MGC-RGD, and lyophilized to obtain MGC 
functionalized with the IKVAV-containing peptide (MGC-IKVAV). 
The degrees of methacrylation and peptide functionalization were determined by proton 
nuclear magnetic resonance (1H NMR) spectroscopy, with targets of 5% for 
methacrylation and 2.5% for peptide functionalization. The peptide-modified pre-
polymers were blended with unmodified MGC in a 40:60 ratio (MGC-peptide to MGC) 
to obtain a final peptide concentration of 1.18 mM for both the MGC-RGD and MGC-
IKVAV groups. 
2.1.2 Hydrogel Physical Characterization 
2.1.2.1 Hydrogel Preparation 
Lyophilized MGC, MGC-RGD or MGC-IKVAV was transferred into a sterile tissue 
culture plate and sterilized by exposure to low-intensity UV light for 30 min. The MGC, 
MGC-RGD and MGC-IKVAV hydrogels were prepared by dissolving the pre-polymer in 
sterile deionized water (for sol content assessment) or PBS (for mechanical 
characterization) at 2.5%, 2.71% and 3.13% (w/v) respectively, to account for differences 
due to the weight of the peptide groups. The pre-polymer was dissolved overnight at 
37°C under agitation at 700 RPM. 
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Stock solutions of ammonium persulfate (APS; BioShop Canada Inc., Burlington, ON) 
and N,N,N’,N’-tetramethylethylenediamine (TEMED; BioShop Canada Inc., Burlington, 
ON) were prepared in water (for sol content assessment) or PBS (for mechanical 
characterization), both at a concentration of 200 mM. For each hydrogel group, a 1 mL 
solution comprising of 95% dissolved pre-polymer, 2.5% APS and 2.5% TEMED was 
prepared and mixed well through gentle stirring. The mixture was transferred into a 1 mL 
syringe and immediately placed in an incubator at 37°C for 15 min to facilitate cross-
linking. 
2.1.2.2 Sol Content Measurement 
The cross-linking efficiency of the unseeded MGC, MGC-RGD and MGC-IKVAV 
hydrogels was determined by measuring the sol content of the hydrogels.140 Immediately 
following cross-linking, the hydrogels were cut into 500 μL samples (n=2) and snap-
frozen in liquid nitrogen. The hydrogels were lyophilized for 12 h and the total dry mass 
(mdry,total) was recorded. Each hydrogel was incubated at 37°C in 2 mL of deionized water 
for 18 hours, with water exchanges at 6-h intervals. Following extraction of the residual 
unreacted pre-polymer, the hydrogels were snap-frozen in liquid nitrogen and lyophilized 
for 12 h. The lyophilized hydrogels were re-weighed to obtain the dry mass of polymer 
incorporated into the network (mdry,network). The sol content was calculated using the 
following equation: 
             Sol	Content	 % = 	 ,-./,12134	5	,-./,67182.9(,-./,12134) 	×	100% 
2.1.2.3 Equilibrium Compressive Modulus Measurement 
Mechanical testing was conducted by Stuart Young (PhD candidate, Amsden lab; 
Queen’s University) to measure the equilibrium compressive modulus of the MGC, 
MGC-RGD and MGC-IKVAV hydrogels.201 Following cross-linking, 50 μL hydrogels 
(n=6) were swollen to equilibrium in PBS (pH 7.4). The dimensions of the swollen 
hydrogels were measured using digital calipers immediately before testing. Unconfined 
stress-relaxation measurements were conducted using a MACH-1™micromechanical 
tester (Biomomentum Inc., Laval, QC) with a 1 kg load cell equipped with an upper steel 
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plate and an advancing steel base. Each hydrogel was placed on the stage in a PBS bath. 
Compression was applied axially at increments of 4% strain at a rate of 10%·s-1 to a total 
strain of 32%, at which point the nominal stress-strain curve achieved plateau. The 
resulting force decay was recorded at each step until an equilibrium stress was reached. 
Nominal stress was calculated from the applied force divided by the initial cross sectional 
area of the sample. The equilibrium compressive modulus was then obtained from the 
slope of the linear region of the nominal equilibrium stress-stain curve. 
2.2 Adipose-derived Stem/Stromal Cell (ASC) Isolation, 
Culture, and Characterization 
2.2.1 Adipose Tissue Collection 
Abdominal and breast adipose tissue samples were collected from female patients 
undergoing elective plastic and reconstructive procedures at the London Health Sciences 
Centre in London, Ontario. Informed consent was obtained prior to surgery, and the study 
was reviewed and approved by the Human Research Ethics Board at Western University 
(REB #105426). Freshly-harvested adipose tissue samples were placed in 100 mL of 
sterile, cation-free phosphate buffered saline (PBS; Lonza, Mississauga, ON) 
supplemented with 20 mg/mL bovine serum albumin (BSA). The samples were 
transported to the lab on ice and adipose-derived stem/stromal cell (ASC) isolation was 
performed within 2 h of tissue collection. Patient age, weight, height and explant site 
were recorded for all donors. 
2.2.2 ASC Isolation 
Human ASCs were isolated using established protocols as described in Flynn et al.202 The 
fresh adipose tissue was finely minced using sterile scissors and any fibrous or cauterized 
tissue was removed from the sample. The minced tissue was added to 25 mL of digest 
solution consisting of 2 mg/mL collagenase type I (Worthington Biochemical Corp., 
Lakewood, NJ), 3 mM glucose, 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) and 20 mg/mL BSA in Kreb’s Ringer Buffer (KRB) to a maximum 
volume of 40 mL. The tissue was enzymatically digested for 45 min at 37°C under 
constant agitation at 100 RPM. Undigested tissue fragments were removed by filtration 
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through a 250 μm pore-size stainless steel filter and the filtrate was allowed to gravity 
separate for 5 min. The upper layer of mature adipocytes was carefully aspirated without 
disturbing the lower layer containing the stromal vascular fraction (SVF), including the 
ASC population. To neutralize the collagenase, an equal volume of complete cell culture 
medium comprised of Dulbecco’s Modified Eagle Medium:Ham’s F12 nutrient mixture 
(DMEM:Ham’s F12), supplemented with 10% fetal bovine serum (FBS; Wisent Bio 
Products, Montreal, QC) and 1% penicillin-streptomycin (pen-strep; Life Technologies 
Inc., Burlington, ON) was added to the sample before centrifugation at 1200 × g for 5 
min. The supernatant was discarded and the cell pellet was resuspended in 20 mL of 
erythrocyte lysing buffer (0.154 M NH4Cl, 10 mM KHCO3 and 0.1 mM EDTA in sterile 
deionized water) for 10 min under agitation at 100 RPM before re-centrifugation. The 
supernatant was aspirated and the cell pellet was resuspended in 20 mL of complete cell 
culture medium. The cell suspension was filtered through a 100 μm pore-size nylon filter, 
and re-centrifuged. The cell pellet was resuspended in complete medium and the cells 
were plated onto T-75 tissue culture polystyrene (TCPS) flasks (Corning, New York, 
USA) at 30,000 cells/cm2. After a 24 h incubation at 37°C (20% O2/5% CO2), the cells 
were washed with 10 mL of sterile PBS to remove unattached cells and cellular debris, 
and the complete medium was replaced. 
2.2.3 ASC Culture and Cryopreservation 
The complete medium was exchanged every 2 days until 80% confluence. Plastic 
adherent cells were released through incubation at 37°C in 0.25% trypsin/0.1% EDTA 
(Life Technologies Inc., Burlington, ON) for 5 min. The passage 1 (P1) cells were 
collected, centrifuged and resuspended in cell freezing medium comprised of 80% FBS, 
10% DMEM:Ham’s F12 medium and 10% dimethyl sulfoxide (DMSO; Fisher Scientific, 
Ottawa, ON) at a concentration of 1 × 106 cells/mL. The ASCs were subjected to a 
controlled freezing protocol using a freezing container at -80 °C (Nalgene, 5100-0001) 
and stored in liquid nitrogen in a cryopreservation unit (Thermo Scientific CY509107) 
until further use. 
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2.2.4 ASC Expansion 
Cryopreserved P1 ASCs were thawed and plated on T-75 flasks at a density of 1 × 106 
cells per flask in complete medium, and cultured at 37°C (20% O2/5% CO2). The 
complete medium was exchanged every 2 days. At 80% confluence, the ASCs were 
trypsin-released and plated on new T-75 flasks in a 1 to 3 ratio. Passage 3 (P3) cells were 
used for all cell characterization and encapsulation experiments. All studies included 2-3 
technical replicates for all scaffold conditions seeded with ASCs from the same donor 
(n=2-3), and the experiments were repeated to have 2-4 biological replicates using cells 
from different donors (N=2-4). 
2.2.5 ASC Immunophenotype Characterization 
ASC immunophenotype was assessed by flow cytometry (n=3, N=3) using a Guava® 
easyCyte 8HT benchtop flow cytometer (EMD Millipore Corp., USA) following 
published protocols.203 Single marker staining was performed with monoclonal 
flourophore-conjugated anti-human antibodies (eBioscience, San Diego, CA) as follows: 
CD90 (Cat. # 11-0909-41), CD44 (Cat. # 25-0441-81), CD29 (Cat. # 12-0299-71), CD73 
(Cat. # 11-0739-41), CD105 (Cat. # 12-1057-41), CD31 (Cat. # 12-0319-42), CD45 (Cat. 
# 11-0459-41), CD146 (Cat. # 11-1469-41) and CD34 (Cat. # 17-0349-41). Controls of 
unstained cells were also included in all analyses. 
Passage 2 (P2) ASCs were trypsin-released, centrifuged and resuspended in complete 
medium. A total viable cell count was performed on the ASCs using the Guava® 
ViaCount Assay (Millipore Corp.). Cells were resuspended at a density of 2.4 × 105 
cells/mL in PBS supplemented with 10% FBS. For each marker, 1 mL of cell suspension 
was transferred into an eppendorf tube, and centrifuged at 1200 × g for 5 min at 4°C in a 
pre-cooled micro-centrifuge. The supernatant was aspirated and the ASCs were 
resuspended in 600 μL of ice-cold PBS supplemented with 3% BSA (PBS + 3% BSA). 
All subsequent steps were performed under minimal lighting. 5 μL of the stock antibody 
solution was added to the cell suspension. The samples were vortexed briefly and 
incubated for 30 min at 4°C. The cells were washed 3 times by centrifuging at 400 × g for 
5 min at 4°C, aspirating the supernatant, and resuspending the ASCs in 600 μL of ice-
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cold PBS + 3% BSA. After the final wash, the cells were fixed in 0.5% paraformaldehyde 
(Fisher Scientific, Ottawa, ON) for 15 min at 4°C. The cells were washed again with ice-
cold PBS + 3% BSA for a total 3 rinses, and then stored in a dark environment at 4°C 
until flow cytometry was performed. 
2.3 ASC Encapsulation within the Hydrogels 
The MGC, MGC-RGD or MGC-IKVAV pre-polymer solution and APS/TEMED 
reagents were prepared in sterile PBS, as described in Section 2.1.2.1. P2 ASCs were 
trypsin-released and resuspended at 5 × 107 cells/mL in complete medium. For each 
hydrogel group, a 1 mL solution comprising of 75% pre-polymer, 20% cell suspension, 
2.5% APS and 2.5% TEMED was prepared and mixed well through gentle stirring. The 
mixture was transferred into a 1 mL syringe and immediately placed in an incubator at 
37°C for 15 min to facilitate cross-linking. Following gelation, the cross-linked hydrogel 
was extruded from the syringe and cut into 50 μL cylinders, each containing ~500,000 
encapsulated ASCs. Each hydrogel was transferred into an individual 12-well insert 
(Greiner Bio-one, North Carolina, USA) and cultured in complete medium. 
To simulate the hypoxic microenvironment prevalent in the extremities of CLI 
patients,115,204,205 the ASC-encapsulated hydrogels were cultured at 37°C under simulated 
hypoxic conditions (2% O2/5% CO2/93% N2) in a Whitley H35 Hypoxystation 
(HypOxygen, Maryland, USA). The complete medium was exchanged every 2 days for 
the duration of the studies. 
2.4 In Vitro Characterization of ASC following 
Encapsulation 
2.4.1 ASC Viability 
ASC viability following encapsulation and culture in the various hydrogel groups (MGC, 
MGC-RGD, MGC-IKVAV) was assessed at 24 h, 7 d and 14 d using the LIVE/DEAD® 
Viability/Cytotoxicity Kit for mammalian cells (Life Technologies Inc., Burlington, ON) 
involving staining with calcein AM and ethidium homodimer-1 (EthD-1) (n=3, N=3). At 
each time point, the hydrogels were rinsed with PBS and stained with 2 μM calcein AM 
  
38 
and 4 μM EthD-1 at 37°C for 1 h. Following incubation, triplicate samples of each 
hydrogel group were imaged using a 5× objective lens on a Zeiss LSM 800 confocal 
microscope (ZEISS, Canada). The mosaic stitch technique was used to capture the entire 
cross-sectional area of the hydrogel.141 A total of 4-5 layers were scanned and imaged for 
each hydrogel along its depth (z-axis), with each layer separated by 50 μm. The images 
were then processed to quantify the number of calcein+ live cells and EthD-1+ dead cells 
using Image J analysis software. The ASC viability was calculated as a percentage of the 
live to total cells, and the average number of live and dead cells per plane was also 
determined for each sample. 
2.4.2 ASC Metabolic Activity 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Life 
Technologies Inc., Burlington, ON) assay was used to measure the metabolic activity of 
ASCs encapsulated in the MGC, MGC-RGD or MGC-IKVAV hydrogels at 24 h, 7 d and 
14 d (n=3, N=3).206 Unseeded hydrogels were also analyzed as a control. A working MTT 
solution (0.5 mg/mL) was prepared in DMEM:Ham’s F12 medium. The hydrogel 
samples were submerged in 2 mL of MTT solution, and incubated at 37°C for 4 hours. 
Following incubation, each hydrogel was washed twice with sterile PBS and weighed. 
The hydrogels were transferred into 1.5 mL eppendorf tubes with 800 μL of DMSO and 
manually crushed using a plastic eppendorf pestle. The samples were then incubated for 1 
h at 37°C under gentle agitation at 100 RPM to extract the water-insoluble formazan 
product. The supernatant was collected following centrifugation at 15,000 × g for 15 min, 
and the samples were diluted 1:1 in DMSO. The samples were vortexed briefly and 200 
μL of sample was pipetted into a 96-well plate in triplicate. Sample absorbance was 
measured at 540 nm and corrected for background absorbance at 690 nm using a 
CLARIOstar® High Performance Monochromator Multimode Microplate Reader (BMG 
Labtech, Guelph, ON). To account for minor differences in gel size, the data was 
normalized based on individual gel weight (mg). The average normalized absorbance of 
the unseeded controls for each of the hydrogel groups was subtracted to account for any 
non-specific background associated with the hydrogels. 
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2.4.3 ASC Angiogenic Gene Expression 
The human angiogenesis RT2 Profiler™PCR array (Qiagen, Toronto, ON) was used to 
assess the mRNA expression of 84 genes associated with angiogenesis in the ASCs 
encapsulated within the MGC, MGC-RGD, and MGC-IKVAV hydrogels (N=4). ASCs 
cultured in 2-D on uncoated TCPS were included as a calibrator to normalize the levels 
between donors. The RNeasy® kit (Qiagen, Toronto, ON) was used to extract the total 
RNA from the hydrogels or TCPS controls cultured under simulated hypoxic conditions 
(2% O2) for 7 d.207 For each hydrogel group, triplicate samples of two hydrogels were 
rinsed with PBS and minced with scissors in 1 mL of TRIzol reagent (n=6 total per 
hydrogel group). The samples were then disrupted using an ultrasonic homogenizer with 
3 sets of 10-second bursts with intervals of cooling on ice, followed by 5 min incubation 
at room temperature. To prepare the TCPS controls, 500,000 P3 ASCs were seeded in 
individual wells of a 6-well plate and cultured under simulated hypoxic conditions (2% 
O2). At 7 d, the cells were rinsed with PBS and incubated in 1 mL of TRIzol reagent for 5 
min. For both the hydrogel samples and TCPS controls, 200 μL of chloroform was added 
and the samples were incubated at room temperature for 10 min before centrifugation at 
10,000 × g for 10 min. The upper aqueous phase was transferred into new 1.5 mL 
eppendorf tubes, and 250 μL of 70% ethanol was added to each sample. The samples 
were transferred to RNeasy mini spin columns and processed according to the 
manufacturer’s instructions. The triplicate samples were pooled (n=6 gels total) and post-
extraction clean-up was performed by adding 0.1× the volume of 3 M sodium acetate, 
2.5× the volume of 100% ethanol, and 0.01× the volume of 5 mg/mL glycerol to the 
aqueous RNA sample. After overnight incubation at -30°C, the RNA was washed with 30 
μL of 80% ethanol 3 times with centrifugation at 12,000 × g for 30 min between each 
wash. The RNA was resuspended in 30 μL of nuclease-free water, and sample 
concentration and purity were determined using a NanoDrop 1000 spectrophotometer 
(Thermo Scientific). 
The RT2 First Strand kit (Qiagen, Toronto, ON) was used to prepare cDNA from the 
extracted RNA. Each sample was first treated with a DNA elimination step by incubating 
400 ng of RNA, 2 μL genomic-DNA elimination buffer and nuclease-free water for 5 
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min at 42°C. Subsequently, 10 μL of the sample was mixed with 10 μL of reverse-
transcription mix containing 5× reverse transcription buffer, primer mix, RT enzyme mix 
and RNase-free water. The samples were incubated at 42°C for 15 min and then at 95°C 
for 5 min to stop the reaction.  
Following manufacturer’s instructions for the PCR reactions, 91 μL of nuclease-free 
water was added to each 20 uL cDNA sample and mixed well through pipetting. The 
PCR component mix was prepared for each sample by mixing 102 μL of the diluted 
cDNA sample with 650 μL of 2× RT2 SYBR Green Mastermix and 548 μL of RNase-free 
water, for a total volume of 1300 μL. For each sample, 10 μL of the prepared PCR 
component mix was dispensed into each well of the 384-well RT2 Profiler PCR array 
plate. The plate was tightly sealed with optical adhesive film and centrifuged for 1 min at 
1000 × g to remove any bubbles. The plate was run on a CFX384 Touch™Real-Time 
PCR detection system (Bio-Rad, Mississauga, ON). The cycle threshold (Ct) values were 
obtained and processed using the online software provided by Qiagen’s data analysis 
center. The stably expressed housekeeping gene, ribosomal protein lateral stalk subunit 
P0 (RPLP0), was used to normalize the data. Fold change in the mRNA expression of the 
84 analyzed genes was used to compare the MGC, MGC-RGD and MGC-IKVAV groups 
normalized to the TCPS control group. Genes displaying >2-fold upregulation or 
downregulation in mRNA expression relative to the TCPS controls across all donors were 
selected and statistically analyzed. 
2.5 In Vivo Characterization of ASC Retention following 
Encapsulation and Angiogenic Response to the 
Hydrogels 
2.5.1 Subcutaneous Implantation of Hydrogels in NOD/SCID Mice 
A subcutaneous implantation model was used to assess cell retention and the angiogenic 
potential of human ASCs encapsulated within the MGC, MGC-RGD or MGC-IKVAV 
hydrogels. The animal studies were reviewed and approved by the Human Research 
Ethics Board at Western University (REB #2016-015). Adult NOD/SCID mice (8-10 
weeks old) used for this study were derived from Jackson laboratories: NOD.CB17-
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Prkdcscid/J; stock number: 001303. The NOD/SCID mice provide a favorable 
microenvironment to support human cell engraftment and function due to reduced innate 
immunity (NOD mutation), and complete T- and B-cell deficiency (SCID mutation).208 
Each mouse was implanted with one seeded hydrogel and its corresponding unseeded 
control. The 50 µL hydrogel samples were subcutaneously implanted on the dorsa of 
each mouse, below each scapula, with surgical assistance from Stephen Sherman (PhD 
candidate, Hess Lab) at the Robarts Research Institute. Two mice were used for each 
hydrogel group and the study was repeated with ASCs from 3 different donors (n=2, 
N=3). 
Prior to surgery, the mice were injected with 42 mg/kg of ketamine hydrochloride and 1 
mg/kg of xylazine, and the animals were maintained on 2% isoflurane (Baxter Corp., 
Mississauga, ON) during the surgical procedure. For each experimental group, one 50 μL 
hydrogel containing ~500,000 encapsulated human ASCs was implanted in a 
subcutaneous pocket created in the right dorsal flank, and a second 50 μL unseeded 
hydrogel was implanted subcutaneously in the left dorsal flank. Mice were given 2 mg/kg 
of metacam after the surgery.  
At 24 h prior to euthanasia, the mice were intraperitoneally injected with 200 μg 5-
ethynyl-2'-deoxyuridine (EdU; Thermo Fisher, Waltham, MA) to label dividing cells. 
After 14 days, the mice were anesthetized with isoflurane and euthanized by cervical 
dislocation, and the scaffolds were excised within their surrounding tissues. The samples 
were embedded in OCT medium (Tissue Tek, Sakura Finetek, Torrance, CA) and 
cryosectioned (10 μm) with assistance from Gillian Bell (Research Assistant, Hess Lab) 
at Robarts Research Institute. 
2.5.2 Detection of Human ASCs and Murine CD31+ Cells 
The sections were analyzed by immunofluorescence microscopy for human leukocyte 
antigen (HLA)-ABC to label human ASCs,209 murine CD31 to visualize CD31+ cell 
recruitment and EdU to assess cellular proliferation,208,209 along with DAPI 
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counterstaining of nuclei. All incubation steps during staining were performed at room 
temperature. 
HLA-ABC staining: Sections were washed twice with PBS for 10 min and permeabilized 
with 0.1% TritonX-100 for 20 min. The sections were washed again with PBS for 10 min 
and incubated with a mouse-on-mouse (MOM) blocking agent (Vector Labs, Burlingame, 
CA) for 1 h. The sections were incubated with MOM diluent for 5 min, and then with 
mouse anti-human HLA-ABC antibody (1:100 dilution in MOM diluent; BD 
Biosciences, Mississauga, ON) for 30 min. Next, the sections were washed twice with 
PBS for 2 min, and incubated with fluorescein-labeled horse anti-mouse IgG (1:200 
dilution in MOM diluent) for 30 min. Finally, the sections were washed twice with PBS 
for 2 min, rinsed with deionized water, and mounted in VectaShield with DAPI (Vector 
Labs, Burlingame, CA). Primary antibody negative controls (HLA-ABC−) were prepared 
by substituting the mouse anti-human HLA-ABC antibody with MOM diluent.209  
EdU and CD31 staining: Sections were washed twice with PBS for 10 min and 
permeabilized with 0.1% Triton X-100 for 20 min. The sections were washed again with 
PBS for 10 min, and incubated for 30 min with EdU labeling cocktail consisting of 860 
μL reaction buffer, 100 μL buffer additive, 40 μL CuSO4 and 2.5 μL Alexa Fluor Azide 
provided in the Click-iT™ imaging kit (Invitrogen, Burlington, ON). The sections were 
washed twice with PBS for 2 min and blocked by incubation in rabbit serum (Vector 
Labs, Burlingame, CA) for 1 h. The sections were then incubated with rat anti-mouse 
CD31 antibody (1:100 dilution in rabbit serum) for 1 h. Next, the sections were washed 
twice with PBS for 2 min and incubated with fluorescein-labeled rabbit anti-rat IgG 
(1:200 dilution in rabbit serum) for 30 min. Finally, the sections were washed twice with 
PBS, rinsed in deionized water, and mounted in VectaShield with DAPI (Vector Labs, 
Burlingame, CA). EdU− controls were prepared by removing the CuSO4 reaction-
catalyzing reagent from the EdU labeling cocktail. Primary antibody negative (CD31−) 
controls were prepared by substituting the primary antibody with rabbit serum.208,209 
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2.5.3 Imagine and Quantification of HLA-ABC+, EdU+ and CD31+ 
Cells 
Analysis of human ASC retention: Images of the immunostained sections were taken 
with an Axioscope Z2 fluorescence microscope (ZEISS Germany), analyzing 8-10 non-
overlapping areas selected randomly within the scaffold per section, from a total of 3 
sections per hydrogel implant using AxioVision software (n=2, N=3). Scaffold area was 
calculated by converting each image to an 8-bit binary copy and using ImageJ software to 
analyze the total scaffold area in mm2. The number of HLA-ABC+ DAPI+ cells were 
counted for each image in a blinded fashion and expressed as the average number of 
HLA-ABC+ DAPI+ cells/mm2 of hydrogel scaffold. 
Analysis of murine CD31+ cell recruitment and proliferation: Images of the 
immunostained sections were taken with an Axioscope Z2 fluorescence microscope, 
analyzing 4-5 areas selected randomly at the scaffold-tissue boundary per section, from a 
total of 3 sections per hydrogel implant using AxioVision software (n=2, N=2). The 
number of CD31+ cells co-localized with visible DAPI-stained nuclei were counted for 
each image in a blinded fashion and expressed as the mean number of CD31+ cells/mm2. 
The number of CD31+ EdU+ DAPI-stained cells were also counted for each image in a 
blinded fashion and reported as the number of proliferating CD31+ cells. 
2.6 Statistical Analysis 
All data are expressed as mean ± standard deviation, and the number of biological (N) 
and technical (n) replicates are indicated for all experiments. Unless otherwise stated, 
statistical analyses were performed using GraphPad Prism 6 by one-way or two-way 
analysis of variance (ANOVA). Multiple comparisons were performed with Tukey’s 
post-hoc comparison of means. Differences were considered statistically significant at 
p<0.05. 
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Chapter 3  
3 RESULTS 
3.1 Hydrogel Characterization 
3.1.1 Sol Content Analysis 
Sol content provides a measure of the amount of the methacrylated glycol chitosan 
(MGC) pre-polymer that has not been incorporated into the hydrogel network during 
cross-linking. A lower sol content value is desirable as it indicates higher cross-linking 
efficiency. In comparing the 3 hydrogel groups, the sol content value for the MGC-
IKVAV group was 15.0 ± 0.9%, which was significantly higher than the values of 7.4 ± 
0.1% for the non-peptide modified MGC group and 8.9 ± 0.9% for the MGC-RGD group 
(Figure 3.1A), thus indicating that modification of the MGC with the IKVAV peptide 
influenced the cross-linking process. 
 
Figure 3.1. Sol content and equilibrium compressive moduli of MGC, MGC-RGD and MGC-
IKVAV hydrogels. (A) The cross-linking efficiency of each type of hydrogel was assessed by 
measurement of the sol content following thermally-induced cross-linking and extraction in deionized 
water (n=2). The MGC-IKVAV hydrogel group had a significantly higher sol content than the other 
hydrogel groups, suggesting that modification with the IKVAV peptide may have interfered with 
cross-linking process. (B) The equilibrium compressive modulus of the three hydrogel groups as 
measured through micromechanical compression testing, confirming that all hydrogels had similar 
mechanical properties (n=6). Data represents mean ± SD (*p<0.05). 
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3.1.2 Equilibrium Compressive Modulus Analysis 
The cross-linking efficiency can influence the mechanical properties of the resultant 
hydrogels. Since the response of encapsulated cells can be impacted by both biochemical 
and biomechanical effects,210–212 the equilibrium compressive moduli of the MGC, MGC-
RGD and MGC-IKVAV hydrogels were quantified to assess whether there were any 
differences in gel stiffness between the groups. Despite the variation in the sol content for 
the MGC-IKVAV group, there were no statistically significant differences in the 
equilibrium compressive moduli of the hydrogels, with calculated values of 11.9 ± 1.3 
kPa for the MGC group, 10.6 ± 2.1 kPa for the MGC-RGD group, and 12.0 ± 0.9 kPa for 
the MGC-IKVAV group (Figure 3.1B). Based on this analysis, it was decided that no 
further optimization of the hydrogel formulation was required, as the equivalent 
compressive moduli controlled for the possible confounding effects of the hydrogel 
biomechanical properties in assessing the impact of the peptide groups on cell function. 
3.2 Adipose-derived Stromal/Stem Cell (ASC) 
Immunophenotype Analysis 
The immunophenotype of passage 3 (P3) human adipose-derived stem/stromal cells 
(ASCs) expanded on tissue culture polystyrene (TCPS) was assessed by flow cytometry 
(Figure 3.2). Consistent with the expected expression of stromal cell markers, ASCs 
dependably expressed CD90 (99.8 ± 0.1%), CD44 (99.6 ± 0.2%), CD29 (95.8 ± 2.6%), 
CD73 (84.7 ± 8.1) and CD105 (97.2 ± 2.2%). Further, ASCs showed minimal expression 
of the endothelial cell marker CD31 (0.3 ± 0.2%) and the hematopoietic pan-leukocyte 
marker CD45 (1.3 ± 1.2%). The pericyte marker CD146 (4.6 ± 3.2%) and the progenitor 
cell marker CD34 (0.6 ± 0.1%) demonstrated low expression, consistent with previous 
studies reporting a steady decline in the expression of these markers during culture and 
successive passaging.100,213,214 Overall, the immunophenotype of the ASCs used in this 
study was consistent with the guidelines established by the International Society of 
Cellular Therapy (ISCT) and the International Federation for Adipose Therapeutics and 
Science (IFATS) for human ASCs.112 
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Figure 3.2. Immunophenotype of human ASCs at passage 3. (A) Representative flow cytometry 
histograms showing expression of analyzed cell surface markers. Unstained controls are shown in 
light grey. (B) Frequency of cells expressing each of the analyzed markers. The ASC 
immunophenotype was consistent with guidelines set forth by the International Federation for Adipose 
Therapeutics (IFATS) and the International Society for Cellular Therapy (ISCT), with high expression 
(>80%) of CD90, CD44, CD29, CD73 and CD105, and low expression (<2%) of CD31 (endothelial) 
and CD45 (hematopoietic). Data represents mean ± SD (p<0.05; n=3, N=3). 
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3.3 ASC Encapsulation within Hydrogels 
Human ASCs at P3 were encapsulated within the MGC, MGC-RGD and MGC-IKVAV 
hydrogels at a concentration of 10 × 106 ASCs/mL through thermally-induced free radical 
polymerization with ammonium persulfate (APS) and N,N,N’,N’-
tetramethylethylenediamine (TEMED) as the initiator system. Immediately after gelation, 
50 μL hydrogel cylinders containing ~500,000 encapsulated ASCs were generated 
(Figure 3.3) and used for all subsequent in vitro and in vivo studies. 
 
Figure 3.3. Representative images of an MGC hydrogel containing encapsulated ASCs. (A) 
Human ASCs were encapsulated within a 50 μL MGC hydrogel at a concentration of 10 × 106 
ASCs/mL. Light photomicrographs taken at 24 h following encapsulation showing the ASCs 
(examples indicated with white arrows) distributed within the MGC hydrogel at (B) 4× and (C) 20× 
magnification. 
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3.4 In Vitro Analysis of ASCs following Encapsulation 
3.4.1 ASC Viability 
The LIVE/DEAD® assay with confocal imaging analysis was used to assess ASC 
viability following encapsulation within the MGC, MGC-RGD or MGC-IKVAV 
hydrogels over 14 days in culture under a simulated hypoxic environment (2% O2) 
(Figure 3.4). Quantitative analysis revealed that ASC viability in the MGC (86.6 ± 4.5%) 
and MGC-RGD (87.4 ± 2.7%) hydrogels was significantly higher than the MGC-IKVAV 
(73.3 ± 12.3%) group at 24 h (Figure 3.4B). The high viability in the MGC and MGC-
RGD groups validated that the radically-induced thermal cross-linking approach using 
APS and TEMED did not adversely impact cell viability. 
Analysis of ASC viability over time revealed that cell viability was also significantly 
reduced in the MGC-IKVAV hydrogel group relative to the MGC and MGC-RGD 
groups at both 7 and 14 d. ASC viability significantly declined from 24 h to 14 d in both 
the MGC and MGC-IKVAV hydrogel groups, from 86.6 ± 4.5% to 75.0 ± 6.6% for the 
MGC group and 73.3 ± 12.3% to 54.4 ± 12.2% for the MGC-IKVAV group (Figure 
3.4B). In contrast, there was no significant difference observed in ASC viability over 
time in the MGC-RGD group, with >80% viability observed over the course of the study. 
To complement the viability analysis, the average number of live and dead ASCs within 
each hydrogel cross-section was plotted for the MGC, MGC-RGD and MGC-IKVAV 
hydrogel groups at each time point (Figure 3.4C). Notably, there was no significant 
difference in the total number of cells per plane (live + dead) for all hydrogel groups. 
However, at both 7 d and 14 d, there was significantly lower number of live cells in the 
MGC-IKVAV group relative to both the MGC and MGC-RGD groups, with a significant 
decline in the number of live cells observed over time from 24 h to 14 d. 
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Figure 3.4. Viability analysis of ASCs encapsulated within MGC, MGC-RGD and MGC-IKVAV 
hydrogels cultured under simulated hypoxic conditions (2% O2). (A) Representative confocal 
microscopy photomicrographs of LIVE/DEAD®-stained ASCs encapsulated within an MGC hydrogel 
at 24 h. Live cells (upper row; green) and dead cells (bottom row; red) were imaged across 4 planes 
within the hydrogel using a mosaic stitch technique to visualize the entire cross-section of the scaffold 
at varying depths. (B) The number of live and dead cells were quantified to assess the percent viability 
of the ASCs in each of the hydrogel groups at 24 h, 7 d and 14 d. The MGC-IKVAV hydrogel had 
significantly lower ASC viability than the other hydrogel groups across each time-point. ASC viability 
declined in the MGC and MGC-IKVAV groups from 24 h to 14 d, but no significant differences in 
viability were observed over time for the MGC-RGD group. (C) The average number of live (lower 
bar) and dead (upper bar) ASCs within each hydrogel group at 24 h, 7 d and 14 d based on the 
LIVE/DEAD® assay. The MGC-IKVAV hydrogel demonstrated a significantly reduced number of 
live ASCs at 7 d and 14 d compared to the other hydrogel groups, as well as a significant decline in 
live ASCs between 24 h and 14 d. Data represents mean ± SD (*p<0.05; n=3, N=3). 
3.4.2 ASC Morphology 
The confocal imaging analysis in the LIVE/DEAD® assay also enabled the assessment of 
qualitative changes in ASC morphology following encapsulation and culture (Figure 3.5). 
At 24 h, the ASCs in all three hydrogel groups had a rounded morphology. Following 
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culture, ASCs with a distinct elongated fibroblastic morphology were observed within the 
two most superficial planes (0-50 µm) of the MGC-RGD hydrogel group, with a 
qualitative increase noted in the frequency of spreading from 7 to 14 d (Figure 3.5E&F). 
In contrast, ASCs encapsulated in the MGC and MGC-IKVAV hydrogels maintained a 
rounded shape over the course of the study. 
 
Figure 3.5. Representative photomicrographs of LIVE/DEAD®-stained ASCs encapsulated 
within MGC, MGC-RGD or MGC-IKVAV hydrogels cultured under simulated hypoxic 
conditions (2% O2). Photomicrographs showing live cells (green) and dead cells (red) within each 
hydrogel group at 24 h, 7 d, and 14 d. White arrows indicate ASCs with an elongated morphology in 
the superficial plane of the MGC-RGD hydrogel group at 7 and 14 d. 
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3.4.3 ASC Metabolic Activity 
In order to more fully examine ASC viability and function following encapsulation 
within the various hydrogels, the MTT assay was performed to assess the metabolic 
activity of ASCs encapsulated within the MGC, MGC-RGD or MGC-IKVAV hydrogels 
over 14 days in culture under simulated hypoxic conditions (2% O2) (Figure 3.6). The 
metabolic activity of the encapsulated ASCs significantly decreased between 24 h and 7 d 
for all hydrogel groups, and was then maintained at similar levels at 14 d. In comparing 
the groups, the ASCs encapsulated within the MGC-IKVAV hydrogels had significantly 
lower metabolic activity than the MGC and MGC-RGD groups at 24 h and 7 d. At 14 d, 
the metabolic activity was significantly higher in the MGC-RGD hydrogels as compared 
to the other groups. 
 
Figure 3.6. Metabolic activity of ASCs encapsulated within MGC, MGC-RGD and MGC-
IKVAV hydrogels cultured under simulated hypoxic conditions (2% O2). The MTT assay was 
performed at 24 h, 7 d and 14 d following ASC encapsulation. The absorption intensity was 
normalized to the gel weight (mg) to account for minor differences in the size of the individual 
hydrogels. All hydrogel groups demonstrated a significant decrease in ASC metabolic activity from 24 
h to 7 d, and then levels were sustained at 14 d. The MGC-IKVAV hydrogel showed significantly 
lower ASC metabolic activity at 24 h and 7 d as compared to the MGC and MGC-RGD hydrogel 
groups. The MGC-RGD hydrogel group demonstrated a significantly higher ASC metabolic activity at 
14 d as compared to both the MGC and MGC-IKVAV groups. Data represents mean ± SD (*p<0.05; 
n=3, N=3). 
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3.4.4 ASC Angiogenic Gene Expression 
The human angiogenesis RT2 Profiler™PCR array was used as a high throughput 
screening approach to assess the potential effects of 3-D hydrogel encapsulation and 
MGC peptide modification on the mRNA expression of 84 genes associated with 
angiogenesis in ASCs encapsulated within the MGC, MGC-RGD or MGC-IKVAV 
hydrogels in comparison to 2-D TCPS controls after 7 days of culture under simulated 
hypoxic conditions (2% O2). Genes that demonstrated >2-fold change relative to the 
TCPS controls across all cell donors (N=4) were selected for further statistical analysis. 
3.4.4.1 Upregulated Angiogenesis-associated Genes 
There was a >2-fold upregulation in gene expression of several secreted angiogenic 
factors including hepatocyte growth factor (HGF), vascular endothelial growth factor A 
(VEGFA), angiopoietin-like 4 (ANGPTL4) and angiopoietin-2 (ANGPT2) in the 
encapsulated ASCs as compared to the TCPS controls (Figure 3.7). In general, the most 
notable differences were associated with culturing the ASCs in the 3-D hydrogels versus 
the 2-D culture conditions, rather than due to the effects of modifying the MGC with the 
peptide ligands. For a number of the genes, there was significant variability in the 
magnitude of the expression between donors, so the data was plotted separately to show 
the response of the individual donors, as well as the averaged values used for statistical 
analysis.   
When comparing the hydrogel groups, a trend for enhanced HGF gene expression was 
noted in the MGC group relative to both peptide-modified MGC groups across all four 
donors. Moreover, the pooled values indicated that there was a significant difference in 
HGF expression between the MGC and MGC-IKVAV groups (Figure 3.7A). For 
VEGFA, ANGPTL4 and ANGPT2, the mRNA expression levels were significantly 
upregulated in the MGC, MGC-RGD, and MGC-IKVAV groups relative to the TCPS 
controls, but there were no notable differences between the various hydrogel groups in 
comparing the response of all cell donors (Figure 3.7B-D).  
A >2-fold upregulation in gene expression was also noted in comparing the hydrogels to 
the TCPS controls for the extracellular matrix (ECM) protein collagen XVIII α1 
  
53 
(COL18A1), the matrix-remodeling factor matrix metalloproteinase 14 (MMP14), and the 
cell adhesion glycoprotein integrin β3 (ITGB3) (Figure 3.8). For COL18A1, there was a 
trend for enhanced mRNA expression in the MGC group relative to the MGC-RGD and 
MGC-IKVAV groups for 3 out of 4 of the cell donors, but the only significant difference 
noted in the pooled values was between the MGC group and the 2-D TCPS control 
(Figure 3.8A). Similarly, for MMP14, significantly higher expression levels were noted 
in the MGC hydrogel group as compared to the TCPS control, but there were no notable 
differences between the hydrogel groups (Figure 3.8B). Finally, while there was a trend 
for enhanced ITGB3 expression in all three hydrogel groups relative to the 2-D controls, 
the difference in the pooled data was not statistically significant and the expression levels 
were relatively consistent across all 3 hydrogel groups (Figure 3.8C). 
3.4.4.2 Downregulated Angiogenesis-associated Genes 
A >2-fold downregulation was observed in the gene expression levels of the secreted 
factors thrombospondin-1 (THBS1), angiopoetin-1 (ANGPT1), connective tissue growth 
factor (CTGF) and fibroblast growth factor 1 (FGF1) in the ASCs encapsulated in the 
hydrogels as compared to the TCPS controls for all cell donors (Figure 3.9). For 3 out of 
4 of the cell donors studied, there was a trend for reduced mRNA expression of the anti-
angiogenic factor THBS1 in the MGC-IKVAV group relative to both the MGC and 
MGC-RGD groups. Moreover, analysis of the pooled data indicated that there was a 
significant difference in the THBS1 expression levels between the MGC-IKVAV group 
and the TCPS controls (Figure 3.9A). Similarly, for 2 of the 4 cells donors, the 
expression of the angiogenic factor ANGPT1 was downregulated in the MGC-IKVAV 
group relative to all other groups, with a significant difference observed in the pooled 
data relative to the TCPS controls (Figure 3.9B). There were no obvious trends in 
comparing the expression levels of CTGF and FGF1 between the hydrogel groups across 
all 4 cell donors (Figure 3.9C&D). However, in analyzing the pooled data, there was a 
significant reduction in CTGF gene expression in the MGC-IKVAV group relative to the 
TCPS controls, as well as significantly lower levels of FGF1 mRNA expression in all 
three hydrogel groups relative to the 2-D controls. 
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Figure 3.7. Gene expression of upregulated secreted angiogenic factors in ASCs encapsulated within MGC, MGC-RGD or MGC-IKVAV 
hydrogels and cultured under simulated hypoxic conditions (2% O2). Results are expressed as fold change in the mRNA expression at 7 d relative to 
TCPS controls. Gene expression of (A) HGF was significantly enhanced in the MGC hydrogel group compared to the TCPS controls, and also compared 
to the MGC-IKVAV hydrogel. Transcript levels of (B) VEGF, (C) ANGPTL4 and (D) ANGPT2 were significantly upregulated for all hydrogel groups 
relative to the TCPS controls, suggesting enhanced transcription of these pro-angiogenic factors in the ASCs encapsulated in the hydrogels. Data shows 
transcript levels from the individual donors (left) and the pooled data from all 4 donors expressed as mean ± SD (right) (*p<0.05; n=6, N=4). 
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Figure 3.8. Gene expression of upregulated ECM-associated factors in ASCs encapsulated within MGC, MGC-RGD or MGC-IKVAV hydrogels 
and cultured under simulated hypoxic conditions (2% O2). Results are expressed as fold change in the mRNA expression at 7 d relative to the TCPS 
controls. Gene expression of (A) the ECM protein COL18A1 and (B) the matrix remodeling factor MMP14 were significantly upregulated in the MGC 
hydrogel group relative to TCPS controls, suggesting enhanced transcription of regulatory and remodeling proteins involved in angiogenic processes in 
the encapsulated ASCs. (C) A trend for enhanced transcript levels of ITGB3 was noted for all hydrogel groups relative to the TCPS controls for all 4 cell 
donors, but the difference was not significant. Data shows transcript levels from the individual donors (left) and the pooled data from all 4 donors 
expressed as mean ± SD (right) (*p<0.05; n=6, N=4). 
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Figure 3.9. Gene expression of downregulated secreted factors in ASCs encapsulated within MGC, MGC-RGD or MGC-IKVAV hydrogels and 
cultured under simulated hypoxic conditions (2% O2). Results are expressed as fold change in the mRNA expression at 7 d relative to the TCPS 
controls. The mRNA expression of (A) THBS1, (B) ANGPT1 and (C) CTGF was significantly decreased in the MGC-IKVAV hydrogel group as 
compared to the TCPS controls. Transcript levels of (D) FGF1 were significantly downregulated in all hydrogel groups relative to the TCPS controls. 
Data shows transcript levels from the individual donors (left) and the pooled data from all 4 donors expressed as mean ± SD (right) (*p<0.05; n=6, N=4).
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3.5 In Vivo Analysis of ASCs following Encapsulation 
3.5.1 ASC Retention within the Implanted Hydrogels 
Human ASCs were encapsulated within the MGC, MGC-RGD or MGC-IKVAV 
hydrogels and subcutaneously implanted into NOD/SCID mice to assess whether peptide 
modification of the MGC influenced ASC retention within the hydrogels in vivo. At 14 d 
post-transplantation, the animals were euthanized to collect the hydrogels, which were 
easily visualized within the subcutaneous space (Figure 3.10A). Immunostaining for 
HLA-ABC was performed to detect human cells (Figure 3.10B), and quantitative analysis 
revealed that there were significantly more HLA-ABC+ cells per unit area in the gel phase 
of the MGC-RGD hydrogel group at 144 ± 31 cells/mm2 as compared to the MGC-
IKVAV hydrogel group at 67 ± 16 cells/mm2 (Figure 3.10C). While there was a trend for 
a higher density of HLA-ABC+ cells in the MGC-RGD group as compared to the non-
peptide modified MGC hydrogel group (103 ± 27 cells/mm2), the difference was not 
statistically significant. 
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Figure 3.10. Analysis of human ASC retention within subcutaneously implanted MGC, MGC-
RGD or MGC-IKVAV hydrogels. (A) Representative photograph of an unseeded (left) and ASC-
seeded (right) MGC hydrogel subcutaneously implanted into NOD/SCID mice and excised at 14 d. 
(B) Representative immunohistochemical photomicrographs of HLA-ABC+ (bright green) and DAPI 
(blue) stained human ASCs within the hydrogels (lighter green due to autofluorescence). (C) Mean 
number of HLA-ABC+ DAPI+ human ASCs/mm2 visualized within each of the hydrogel groups. The 
MGC-RGD hydrogel showed significantly higher ASC retention within the scaffold at 14 d as 
compared to the MGC-IKVAV hydrogel group. Data represents mean ± SD analyzing 8-10 non-
overlapping frames within the scaffold per section, from a total of 3 sections per hydrogel sample 
(*p<0.05; n=2, N=3). 
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3.5.2 CD31+ Cell Recruitment and Proliferation in the Peri-implant 
Region 
Murine endothelial cell (EC) and myeloid cell recruitment and proliferation were 
assessed within the host tissues in the peri-implant region (Figure 3.11) immediately 
adjacent to the MGC, MGC-RGD and MGC-IKVAV implants at 14 d through 
immunostaining for CD31, combined with EdU incorporation to detect proliferating 
CD31+ cells (Figure 3.12A). CD31, named platelet-derived endothelial cell adhesion 
molecule, is a well-accepted endothelial cell marker, but is also expressed on early 
myeloid cells and macrophages.215 Unseeded control hydrogels were also included in the 
analysis to more fully characterize the influence of the encapsulated ASCs versus the 
hydrogel alone on CD31+ cell recruitment in vivo. 
 
Figure 3.11. Representative immunohistochemical photomicrograph showing the peri-implant 
region in the subcutaneous hydrogel implants. The peri-implant region was identified by DAPI 
nuclear staining as the dense cell layer immediately adjacent to the implanted hydrogel. 
Photomicrograph shows CD31+ cells (green) and proliferating cells (EdU+, pink nuclei; examples 
indicated with white arrows) within the peri-implant region at 14 d post-transplantation. 
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A significantly higher number of murine CD31+ cells were detected in the surrounding 
tissues of the ASC-seeded MGC (168 ± 5 cells/mm2) and MGC-RGD (161 ± 12 
cells/mm2) hydrogels as compared to their corresponding unseeded controls (89 ± 14 
cells/mm2 and 94 ± 7 cells/mm2, respectively) (Figure 3.12B). In contrast, there was no 
difference noted in CD31+ cell recruitment between the seeded (113 ± 31 cells/mm2) and 
unseeded (97 ± 4 cells/mm2) hydrogels for the MGC-IKVAV group. Analysis of EdU 
incorporation indicated that there were proliferating CD31+ cells in the peri-implant 
regions. However, there was significant variability in the number of proliferating cells, 
with no statistically significant differences observed between any of the groups (Figure 
3.12C). 
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Figure 3.12. Analysis of CD31+ cell recruitment and proliferation in the peri-implant region of 
subcutaneously-implanted MGC, MGC-RGD or MGC-IKVAV hydrogels. (A) Representative 
photomicrographs of CD31+ (green) and proliferating cells (EdU+, pink nuclei) within the host tissues 
surrounding the ASC-seeded or unseeded hydrogels at 14 d post-transplantation. (B) Mean number of 
CD31+ cells recruited to the peri-implant region for each type of hydrogel with or without ASCs. 
ASC-seeded MGC and MGC-RGD hydrogels had a significantly higher number of CD31+ cells within 
the peri-implant region as compared to their corresponding unseeded controls, suggesting that ASCs 
may provide paracrine signals that promote CD31+ cell recruitment. (C) Frequency of CD31+ EdU+ 
cells within the peri-implant region of the ASC-seeded and unseeded hydrogel groups. No significant 
differences in CD31+ proliferation were observed between any of the groups. Data represents mean ± 
SD analyzed from 4-5 non-overlapping frames at the scaffold-tissue boundary per section, from a total 
of 3 sections per hydrogel sample (*p<0.05; n=2, N=2). 
  
62 
Chapter 4  
4 DISCUSSION 
There is growing interest in the design and application of biomaterials as cell delivery 
vehicles to improve the efficacy of cell-based treatments for peripheral artery disease 
(PAD). A range of synthetic, semi-synthetic and naturally-derived biomaterials have been 
explored to enhance the localization, retention and function of pro-regenerative cell 
populations.85 Notably, hydrogels have shown promise as cell delivery scaffolds for 
therapeutic angiogenesis due to their capacity to cross-link in situ under mild conditions 
to enable minimally-invasive cell delivery via intramuscular injection.216 Hydrogels also 
have high water content similar to that of the native extracellular matrix (ECM), which 
allows for efficient nutrient exchange and supports in vivo integration with minimal 
mechanical irritation to the surrounding tissues.216 Therefore, a major focus of current 
research in the biomaterials field is on the design of novel hydrogel-based cell-delivery 
platforms. Overall, the goal in these strategies is to provide a cell-supportive and 
bioactive microenvironment for transplanted cells to support their sustained localization, 
viability and pro-regenerative secretory functions.217 
Chitosan has emerged as a promising biomaterial due to its cytocompatible, 
biodegradable, antimicrobial, and pro-angiogenic properties.170–172,218 The cationic nature 
of chitosan supports its interactions with negatively-charged glycosaminoglycans (GAGs) 
and proteoglycans, which naturally sequester growth factors and cytokines from within 
the ECM.175 The innate wound healing properties of chitosan are well recognized. For 
example, in a canine wound model, chitosan scaffolds were shown to enhance the 
infiltration of polymorphonuclear cells, stimulate the production of collagen type III by 
fibroblasts, and promote granulation tissue formation at the wound site to accelerate 
wound closure.219 The immunomodulatory properties of chitosan and its oligomeric 
degradation products have been postulated to be associated with its pro-regenerative 
characteristics.174 More specifically, chitosan has been shown to promote macrophage 
recruitment,220 as well as polarization of macrophages towards a more anti-inflammatory 
(M2) phenotype that is associated with enhanced tissue regeneration.221 
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Chitosan is generally insoluble in aqueous media under neutral and basic pH 
conditions.177 Therefore, for cell delivery applications, chitosan is often modified to 
generate glycol chitosan (GC), which is soluble in aqueous solutions at physiological 
pH.140,177 Chitosan contains reactive functional groups that can serve as targets for 
chemical modification, such as methacrylation, to generate N-methacrylate glycol 
chitosan (MGC) that can be cross-linked to form a stable hydrogel network via UV- or 
thermally-initiated cross-linking.140,178 More specifically, in previous studies in the 
Amsden lab, photopolymerization of MGC has been explored using the photoinitiator 
Irgacure 2959 with low intensity UV light to produce hydrogel scaffolds for tissue 
engineering and growth factor delivery.140,141 Amsden et al. initially showed that MGC 
with a 5% degree of substitution (DOS; methacrylate groups per 100 disaccharide units) 
cross-linked with high efficiency following UV irradiation (25 mW/cm2) for 5 min.140 
The hydrogels supported the viability of C-28/I2 cells (human chondrocyte cell line) 
seeded on the scaffold surface over 7 days.140 A later study demonstrated that human 
adipose-derived stem/stromal cells (ASCs) encapsulated in the MGC hydrogels via UV-
initiated cross-linking (10.8 mW/cm2; 3 min) maintained an average viability of 62.2% 
over 14 days.141 Although UV cross-linking enables rapid and efficient gelation of MGC, 
the need for direct exposure to a UV light source at the site of administration limits the 
clinical applicability of this approach for patients with PAD.  
In the present study, a chemical initiator system consisting of ammonium persulfate 
(APS) and N,N,Nʹ,Nʹ-tetramethylethylenediamine (TEMED) was used to cross-link the 
MGC-based pre-polymers at 37ºC, thereby encapsulating human ASCs within the 
hydrogel. This strategy allows for easy handling of the pre-polymer/cell suspension due 
to the slow rate of cross-linking at room temperature, while enabling the delivery of 
regenerative cells into ischemic tissues through minimally-invasive injections via a small 
gauge needle. The efficacy of these initiators has been previously shown in vitro to 
encapsulate rat bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) in 
oligo[poly(ethelene glycol) fumarate] hydrogels.144 Similarly, Hong et al. used the 
thermally-sensitive cross-linking approach to encapsulate rabbit chondrocytes in 
chitosan-based gels and observed maintenance of cell number within the hydrogels over 6 
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days, further confirming the cytocompatibilty of the chemical initiators.178 In addition, the 
efficacy of the APS/TEMED initiator system has been demonstrated in vivo with 
methacrylated hyaluronic acid (MeHA) hydrogels in an ovine myocardial infarction (MI) 
model.129  
Modification of scaffolds with bioactive moieties has allowed researchers to further 
control the fate of transplanted cells, influencing their viability, proliferation, migration 
and differentiation.222 In particular, short integrin-binding sequences derived from ECM 
molecules have been explored to promote cell adhesion, retention and survival within 
otherwise bio-inert scaffolds.223–225 These small peptides offer several advantages as 
compared to the incorporation of complete proteins, including higher stability with 
temperature and pH variations, easier characterization, and cost-effective synthesis.226,227 
Building upon these concepts, one of the main objectives of the present study was to 
investigate the effects of incorporating the integrin-binding RGD and IKVAV peptide 
ligands on human ASC viability, retention and function following encapsulation in the 
MGC hydrogels. 
Due to its widespread distribution in various ECM proteins, the arginine-glycine-aspartic 
acid (RGD) motif found in collagen and fibronectin is one of the most extensively studied 
sequences in the biomaterials field.145 One study demonstrated that incorporating RGD 
motifs within poly(ethylene glycol) (PEG) hydrogels enhanced the survival of 
encapsulated human BM-MSCs, increasing the viability from 15 ± 7% to 73 ± 7% after 1 
week in culture.228 In addition, BM-MSCs seeded onto the surface of the PEG-RGD 
hydrogels showed improved cell attachment and spreading within 4 hours of seeding as 
compared to the unmodified controls.228 Salinas et al. reported that human BM-MSCs 
encapsulated in PEG hydrogels with covalently tethered RGD ligands were able to 
maintain their viability at 84% over a 14-day culture period.229 In a previous study with 
ASCs, rat preadipocytes were shown to bind preferentially to laminin-derived ECM 
substrata as compared to fibronectin- and collagen I or IV-derived ECM substrata,166 
providing a rationale for the exploration of the laminin-derived IKVAV peptide group in 
the current study. While laminin-derived peptides have been less extensively explored in 
the literature to date, Patel et al. demonstrated that incorporating YIGSR motifs in PEG 
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hydrogels improved cell adhesion and increased cell proliferation of rat preadipocytes 
seeded onto the scaffold surfaces, as evidenced by the 4.5-fold increase in DNA content 
over a 6-day culture period.230  
With the recognition that cell response is mediated by the biochemical and biomechanical 
properties of the local cellular microenvironment,210–212 the initial experiments focused on 
the physical characterization of the hydrogels. Analysis of the sol content revealed a 
lower cross-linking efficiency for the MGC-IKVAV hydrogel as compared to the MGC 
and MGC-RGD groups. One possible reason for this difference is that the larger IKVAV 
peptide, comprised of 19 amino acids (CSRARKQAASIKVAVSADR), may have 
sterically hindered the cross-linking process to a greater extent than the shorter 8 amino 
acid sequence of the RGD peptide (GGGGRGDS). The 19-mer IKVAV sequence was 
selected for the current study based on previous work that indicated it had favorable 
bioactive effects on cells in culture.231–233 A concern with using untested shorter 
sequences was that the peptides might not have an appropriate 3-D conformation to 
support integrin binding. However, the length and hydrophobic nature of the 19-mer 
IKVAV peptide, attributed to the relative abundance of hydrophobic alanine (A), 
isoleucine (I) and valine (V) amino acid residues, may have had inhibitory effects on 
cross-linking. This possibility is supported by the fact that challenges were encountered 
when attempting to dissolve the MGC-IKVAV material to obtain an aqueous pre-
polymer solution, which necessitated blending of unmodified MGC with the peptide-
modified MGC to be able to create stable gels with the MGC-IKVAV. While there were 
no issues dissolving the more hydrophilic MGC-RGD pre-polymer, it was also blended in 
a 40:60 ratio with unmodified MGC to ensure there were an equivalent number of peptide 
moieties between the two groups for comparative purposes. While the blended pre-
polymers appeared macroscopically homogenous, it is possible that the more poorly 
soluble MGC-IKVAV may not have incorporated into the hydrogel network as 
efficiently.  
The sol content is an important design consideration, as the presence of unreacted 
methacrylate may negatively impact cell viability.234 However, the primary goal in 
fabricating the hydrogels in the current study was to ensure that the scaffolds had similar 
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equilibrium compressive moduli to assess the impact of the peptide modification of MGC 
on the response of the encapsulated cell populations without the potentially confounding 
biomechanical effects. Scaffold stiffness has been shown to influence cell adhesion, 
cytoskeletal organization, motility and differentiation capacity.212,235,236 For example, a 
previous study showed that the rate of proliferation of human dermal fibroblasts cultured 
on collagen matrices was dependant on scaffold stiffness.237 Specifically, fibroblasts 
seeded on stiffer matrices (143 kPa) showed an 87% increase in cell number, while there 
was only a 25% increase on softer the matrices (42 kPa) over a 2-day culture period.237  
For the cell culture studies, human ASCs were selected as the regenerative cell type due 
to their accessibility, relative abundance, and documented capacity to secrete a broad 
array of pro-angiogenic paracrine factors.93,102–104 These cells have been studied 
extensively in the Flynn lab, and previous work has validated that the ASCs isolated with 
the established culture protocols have multipotent differentiation capacity towards the 
adipogenic, osteogenic and chondrogenic lineages.203,238 The immunophenotype analysis 
of the passage 3 (P3) human ASCs used in the current study confirmed that the cells had 
the expected stromal cell phenotype prior to encapsulation. The flow cytometry data was 
in agreement with the International Society of Cellular Therapy (ISCT) and the 
International Federation for Adipose Therapeutics and Science (IFATS) guidelines for 
ASCs as a stromal cell population,112 with >80% positive stromal marker expression and 
<2% negative marker expression. The variable expression of CD34 and CD146 was also 
consistent with previous reports showing a steady decline in the expression of these 
markers with serial passaging.100,213 
Following the initial characterization of the hydrogels and ASCs, subsequent in vitro 
studies focused on examining the effects of incorporating the peptide-modified MGC 
formulations containing the cell-adhesive RGD or IKVAV sequences within the 
hydrogels on ASC viability following encapsulation and culture under simulated hypoxic 
conditions (2% O2). Notably, the unmodified MGC hydrogels supported high levels of 
ASC viability over the 14-day culture period, although there was a statistically significant 
decline in viability from 24 h to 14 days. In general, the viability results suggest that the 
MGC base material provides a cell-supportive microenvironment, and validates the use of 
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the thermally-induced cross-linking approach with APS and TEMED for ASC 
encapsulation.  
The investigation of the RGD-modified MGC was motivated in part by the pro-survival 
effects noted in previous collaborative studies in the Amsden and Flynn labs with human 
ASCs.141 More specifically, the team demonstrated that photocross-linked MGC 
hydrogels grafted with the RGD peptide maintained the viability of encapsulated ASCs 
above 85% over 14 days in culture under atmospheric conditions, relative to the average 
viability of ~62% in the unmodified controls.141 In contrast, in the current study, the 
viability in the MGC and MGC-RGD groups were quite similar. However, the MGC-
RGD group was the only one that demonstrated no statistically significant changes in 
viability over time, suggesting that the inclusion of the RGD peptides may be favorable 
for long-term ASC survival. In addition to the cross-linking approach, one key difference 
with the previous study was that all culturing in the current study was performed under 
simulated hypoxic conditions (2% O2), which may have enhanced the survival of the 
encapsulated ASCs across all groups, including the unmodified MGC hydrogel. This 
possibility is supported by the work of Stubbs et al., who showed that preconditioning 
human ASCs under hypoxic conditions attenuated cell apoptosis.120 
In contrast, ASC viability in the MGC-IKVAV hydrogel group was significantly reduced 
at all time points as compared to the MGC and MGC-RGD groups, with 54.4 ± 12.2% 
viability observed at 14 days. A possible reason for the poor initial survival of the ASCs 
in the MGC-IKVAV hydrogels at 24 h could be the higher proportion of uncross-linked 
methacrylate groups in this scaffold associated with the higher sol content, which may 
have had adverse effects on the cells.239 More importantly, the decline in ASC viability 
over 14 days indicates that the inclusion of the IKVAV peptide limited the 
cytocompatibility of the MGC scaffolds. It is possible that the hydrophobic nature of the 
IKVAV-containing peptide may have promoted interactions with the plasma membrane 
that were detrimental to cell viability. For example, hydrophobic peptides have been 
applied as cell-penetrating peptides for peptide and protein delivery.240 While past studies 
using the same 19-mer IKVAV peptide have not reported impaired viability, one key 
difference is that the cell response was previously explored in cells cultured on peptide-
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modified 2-D surfaces.232,233 Therefore, it is possible that the interaction between the cells 
and the peptide groups could vary substantially following encapsulation within a 3-D 
microenvironment. Future studies could probe whether the 3-D configuration was a factor 
by exploring ASC attachment and viability on the surface of pre-formed MGC-IKVAV 
hydrogels in comparison to unmodified MGC controls. 
Further analysis of the confocal imaging results in the viability study revealed that the 
total number of ASCs within all of the hydrogel groups remained relatively constant over 
the course of 14 days. These findings suggest that the ASCs did not proliferate within the 
hydrogels during culture. Similar findings have been previously reported with human 
ASCs encapsulated within MGC hydrogels with varying degrees of RGD 
functionalization (0%, 2% and 5%), showing no differences in the number of ASCs over 
a 14-day culture period.141 Likewise, Duggal et al. also demonstrated that the number of 
human ASCs remained constant over 21 days when encapsulated in alginate scaffolds 
covalently modified with the GRGDSP peptide sequence.241 In the future, additional 
studies could be performed using complementary assays such as quantification of total 
dsDNA content to validate the LIVE/DEAD® imaging results, confirming that there 
were no changes in total cell number over time within the hydrogels.  
The LIVE/DEAD® assay also allowed for the qualitative assessment of ASC 
morphology within the hydrogels. The findings suggest that the RGD peptide promoted 
ASC spreading within the superficial layers of the hydrogels, with a fraction of the 
encapsulated cells in the MGC-RGD group having an elongated fibroblastic morphology 
at 7 and 14 days. A previous study has reported similar findings with human BM-MSCs 
seeded onto the surface of MeHA scaffolds.210 Specifically, MeHA scaffolds modified 
with varying RGD peptide densities demonstrated a concentration-dependent increase in 
cell adhesion and spreading area over 14 days. The study’s findings also indicated that 
these morphological changes were attributed to vinculin-rich focal adhesions formed at 
the periphery of the well-spread MSCs in the higher density RGD-modified MeHA 
hydrogels.210 Similarly, Burdick et al. reported that PEG hydrogels modified with RGD 
ligands increased osteoblast spreading within 24 h of seeding on the surface of the gels.242 
Several other authors have reported similar effects in terms of cell adhesion and 
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spreading when incorporating RGD ligands into various scaffolds including alginate gels, 
and N-isopropylacrylamide and acrylic acid-based hydrogels.183,243  
In contrast to the results observed for the MGC-IKVAV group in the current study, a 
previous study showed that IKVAV peptide coatings on 2-D tissue culture polystyrene 
(TCPS) increased murine myoblast attachment and spreading as compared to uncoated 
controls within 3 h of seeding.244 More recently, Li et al. reported that human neural 
stem/progenitor cells cultured on the surface of IKVAV-modified PEG hydrogels 
displayed a spread morphology, with migration into the scaffolds observed at 7 days.245 
However, a key difference is that these studies involved 2-D systems rather than 3-D cell 
encapsulation, and many cell types have a more rounded morphology within 3-D in vivo 
microenvironments than what is observed in 2-D culture systems.246 Another notable 
difference is that Li et al. incorporated a shorter 12 amino acid sequence 
(CCRRIKVAVWLC) in their PEG hydrogels, which may have interacted with the cells 
differently than the peptide used in the current study. In addition, peptide conformation247 
and concentration169 have also been shown to influence the interaction between cells and 
the IKVAV peptides, thereby impacting cell attachment and viability. Future studies 
could explore the effects of varying concentrations of the peptides, including more 
detailed analysis of the structure of the cytoskeleton using immunohistochemistry to 
assess differences in cell morphology. While cell spreading within the hydrogels is an 
indication of altered phenotype, the effects on cell function are not yet clear and may be 
an interesting area for future exploration.248 
While the LIVE/DEAD® assay allowed for the direct assessment of the number of live 
and dead ASCs within the hydrogels, the MTT assay was performed to probe the 
metabolic activity of the encapsulated ASCs within the hydrogels. The attenuated 
metabolic activity in the MGC-IKVAV group at 7 and 14 days was likely attributed to 
the decline in the number of viable ASCs over the course of the study. However, while 
this assay is commonly used as a measure of cell proliferation, cellular metabolic activity 
can be altered for other reasons, with notable variations observed in cell responses 
between 2-D and 3-D culture systems.249 For example, cells at different densities 
demonstrate different metabolic activities, which may not correlate in a linear fashion.249 
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The increased metabolic activity observed at 24 h for all hydrogel groups may have been 
associated with the cells responding to the redox-initiated cross-linking process used for 
encapsulation, with effects subsiding over time. Notably, the findings also indicated that 
the metabolic activity of the encapsulated ASCs was augmented in the MGC-RGD 
hydrogels at 14 days as compared to the other groups. Combined with the observed cell 
spreading, this data could support that there may be differences in ASC function after 
encapsulation in the MGC-RGD hydrogels at the later time points. In another study with 
human BM-MSCs encapsulated within RGD-grafted alginate scaffolds, metabolic 
activity initially declined over 14 days, but rebounded at 21 d to the same levels 
measured at 1 d.160 Therefore, it may be interesting to explore the viability and metabolic 
activity of the ASCs encapsulated in the MGC-RGD and MGC hydrogels at later time 
points in future work. 
With a view towards the future application of the platforms in pro-angiogenic cell 
therapies for the treatment of PAD, the final in vitro studies focused on assessing the 
expression of angiogenesis-associated genes in ASCs encapsulated within the hydrogels 
cultured under simulated hypoxic conditions (2% O2) for 7 days relative to 2-D TCPS 
controls. Overall, the most notable differences were observed between the 3-D and 2-D 
culture conditions, indicating that encapsulation within the 3-D microenvironment altered 
cell function. These findings are consistent with a growing body of literature that 
supports that cell behavior, including proliferation, differentiation, and responses to 
various stimuli, differ substantially when cells are cultured on 2-D substrates as 
compared to 3-D culture systems or in vivo.250,251 For example, variations in the surface 
chemistry and biomechanical properties of the 3-D hydrogels and rigid 2-D TCPS 
substrates252 may have contributed to the differences in angiogenic gene expression in the 
ASCs cultured on these two platforms. It is also worth noting that the ASCs cultured on 
TCPS were not exposed to the free-radical initiator system with APS and TEMED, which 
may have impacted ASC function. Regardless of the differences, the 2-D TCPS controls 
were useful as a calibrator to normalize the gene expression levels and allow for 
comparisons between the different donors. 
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While this study is the first to apply a high throughput approach, these findings are 
supported by previous work investigating the effects of 3-D culture conditions on pro-
angiogenic gene expression. For example, enhanced VEGF gene expression was observed 
in human ASCs seeded on polyglycolic acid/polylactic acid scaffolds relative to 2-D 
culture controls at 14 and 21 days.253 Similarly, higher levels of VEGFA, HGF, FGF-2 
and SDF-1 gene expression were reported in murine ASCs cultured within collagen-
pullulan hydrogels over 48 h as compared to TCPS controls.254 
In terms of the effects of the peptide modification, with the exception of hepatocyte 
growth factor (HGF), there were no statistically significant differences in the gene 
expression levels of the 84 analyzed angiogenic markers between the MGC, MGC-RGD 
and MGC-IKVAV hydrogel groups under the hypoxic culture conditions (2% O2) in the 
current study. It is worth noting that the gene expression levels for HGF and connective 
tissue growth factor (CTGF) demonstrated a >80-fold change in the hydrogel groups as 
compared to the TCPS controls. However, it is also important to recognize that the 
response may vary over time, and that gene expression levels do not always directly 
correlate with protein expression levels. Therefore, it would be worthwhile to explore 
additional time points in future work, such as the 14-day time point, where there were 
notable differences in cell spreading and metabolic activity in the MGC-RGD group. 
Further, it would be interesting to perform additional follow-up studies using ELISAs or 
cytokine arrays to quantify secreted factors in media conditioned by encapsulated ASCs 
at the protein level. 
In terms of the secreted pro-angiogenic factors, there was enhanced gene expression of 
HGF, vascular endothelial growth factor A (VEGFA), angiopoietin-like 4 (ANGPTL4) 
and angiopoietin-2 (ANGPT2) in ASCs encapsulated in the hydrogels relative to the 2-D 
controls. These factors have been shown to play key roles during vascular regeneration, 
including promoting endothelial cell migration and proliferation,255 regulating vessel 
permeability,256,257 and modulating wound healing.258 For example, both HGF and VEGF 
can induce pro-survival effects on the endothelium under hypoxic conditions,259,260 and 
angiopoietin-like 4 has been shown to promote MSC survival under hypoxic 
conditions.261 The ECM-associated genes collagen XVIII α1 (COL18A1), matrix 
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metalloproteinase 14 (MMP14) and integrin β3 (ITGB3) were also upregulated in the 
hydrogel groups as compared to the TCPS controls, consistent with previous reports of 
enhanced MMP and integrin expression in 3-D culture systems.262 Therefore, culturing 
the ASCs within the hydrogels enhanced the expression of genes associated with ECM 
remodeling,263,264 cell adhesion,147 and cell survival.155 For example, MMP14 has been 
shown to activate other proteases including MMP2 and MMP13 to facilitate degradation 
of ECM components and support vascular remodeling.263,264  
While more factors were upregulated, there were several angiogenesis-associated genes 
that were consistently downregulated in the ASCs encapsulated in the hydrogels relative 
to the TCPS controls, including the secreted factors angiopoietin-1 (ANGPT1), CTGF 
and fibroblast growth factor 1 (FGF1), which play a role in promoting endothelial cell 
(EC) proliferation, migration and survival,265–268 as well as vascular stabilization.269 While 
the upregulated angiopoietin-2 is associated with pro-angiogenic sprouting, angiopoietin-
1 reduces endothelial cell permeability and enhances vessel stabilization through mural 
cell recruitment.270 As such, expression of this paracrine factor may be more critical 
during the later stages of regeneration. Interestingly, gene expression of the anti-
angiogenic factor thrombospondin-1 (THBS1) was also downregulated in the hydrogel 
groups as compared to the TCPS controls. THBS1 is a potent inhibitor of angiogenesis 
that exerts its effects on EC proliferation, migration and apoptosis by antagonizing VEGF 
and FGF activity.271,272 While these studies provide some preliminary insight into the pro-
angiogenic capacity of the ASCs encapsulated within the hydrogels, further investigation 
is required to probe the response over time and more fully assess the biological relevance 
of these findings, including analysis of protein expression levels.  
Following the in vitro studies, the hydrogels were subcutaneously implanted into 
NOD/SCID mice to compare ASC retention and the induction of angiogenesis between 
the MGC, MGC-RGD and MGC-IKVAV groups at 14 days. The highest cell density was 
observed in the MGC-RGD implants, which was significantly different than the MGC-
IKVAV group. These results are consistent with the in vitro findings that indicated that 
long-term viability was impaired in the MGC-IKVAV group and improved in the MGC-
RGD. In comparing the MGC and MGC-RGD groups, a relatively high density of 
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encapsulated ASCs could be visualized in both groups, suggesting that the hydrogels also 
supported local cell retention. Based on the observed trends, it is possible that increasing 
the peptide concentration beyond 2.5% in the MGC-RGD group could further augment 
cell adhesion and retention, as concentration-dependent effects on cell viability and 
attachment have been previously reported with human BM-MSCs encapsulated in RGD-
modified HA hydrogels.210  
As a surrogate measure of tissue revascularization, subsequent analyses focused on 
assessing murine CD31+ cell recruitment and proliferation in the peri-implant regions. In 
comparing the unseeded hydrogel groups, the findings suggest that all of the hydrogels 
promoted similar levels of CD31+ cell recruitment, which may be attributed to the pro-
regenerative nature of the MGC base material, as discussed previously.170–172,218 For 
example, the pro-angiogenic qualities of chitosan were shown in a previous study where 
EC recruitment and vascularization were enhanced in the periphery of collagen-chitosan 
composites implanted subcutaneously in mice as compared to collagen-only controls.273 
In assessing the ASC-seeded groups, CD31+ cell recruitment was significantly enhanced 
in the peri-implant region of the ASC-seeded MGC and MGC-RGD groups as compared 
to the unseeded controls. These findings suggest that ASCs encapsulated within these 
hydrogels secreted paracrine factors that promote CD31+ cell migration to the implant 
interface. Similar pro-angiogenic paracrine effects have been previously reported with 
autologous BM-MSCs delivered in HA scaffolds in a subcutaneous rat model,274 as well 
as with human ASCs delivered on collagen scaffolds in a nude rat model.275 The 
consistency in the CD31+ cell recruitment frequencies in the MGC and MGC-RGD 
groups is concordant with the similar viability and angiogenic gene expression profiles 
observed for these two groups in the in vitro studies. In contrast, the lack of ASC-
mediated cell recruitment observed in the MGC-IKVAV implants is consistent with the 
in vitro findings that cell viability was lower in this group. Analysis of cell proliferation 
within the peri-implant region through semi-quantitative measurement of CD31+ EdU+ 
cells was suggestive of pro-angiogenic processes being induced in all of the groups. 
Overall, these in vivo findings support that the MGC and MGC-RGD hydrogels are 
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promising platforms for ASC delivery to promote local cell retention, viability, and 
beneficial paracrine factor production for applications in therapeutic angiogenesis. 
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Chapter 5  
5 CONCLUSIONS 
As the prevalence of peripheral artery disease (PAD) in North America rises, current 
treatments and surgical interventions remain limited in their efficacy to stimulate new 
blood vessel growth, restore long-term perfusion and promote functional recovery in the 
affected limb(s).1,4,14 As such, there is a critical need for new clinically-translatable 
therapies that enhance perfusion in the affected tissues, minimize the risk of disease 
progression and improve the quality of life for patients with PAD. First generation cell-
based therapies involving the injection of mesenchymal stem/stromal cell (MSC) 
suspensions into ischemic tissues have shown potential for stimulating new blood vessel 
formation.58–60 However, the poor survival and retention of transplanted cells limits the 
pro-regenerative and pro-angiogenic functions of MSCs at the target ischemic sites.85–87 
To address these issues, the current project investigated an integrative approach 
combining cell-based therapy with a scaffold-based cell delivery strategy. Specifically, 
the survival and function of human adipose-derived stem/stromal cells (ASCs) was 
examined following encapsulation in N-methacrylate glycol chitosan (MGC) hydrogels. 
To further tune the approach, the MGC polymer was modified with integrin-binding 
RGD or IKVAV peptide ligands to assess the effects of these bioactive moieties in 
promoting ASC viability, retention and function within the hydrogels. 
5.1 Summary of Findings 
Prior to the cell-encapsulation studies, the initial experiments focused on characterizing 
the hydrogel scaffolds and the passage 3 (P3) human ASCs. While the sol content 
revealed that the MGC and MGC-RGD groups had a higher cross-linking efficiency than 
the MGC-IKVAV group, the equilibrium compressive moduli across all groups were 
similar, thus confirming consistent biomechanical properties which could potentially 
impact cell function. The immunophenotype analysis confirmed that the P3 ASCs aligned 
with the guidelines set forth by the International Society of Cellular Therapy (ISCT) and 
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the International Federation for Adipose Therapeutics and Science (IFATS) for stromal 
cell population.112 
For aim 1, in vitro analyses were conducted to assess ASC viability, cell morphology and 
metabolic activity following cell encapsulation within the MGC, MGC-RGD or MGC-
IKVAV hydrogels over 14 days in culture under hypoxic culture conditions (2% O2) 
simulating the ischemic limb. The results demonstrated that ASCs encapsulated in the 
MGC and MGC-RGD hydrogels were able to maintain high viability (>75% and >80%, 
respectively) over the 14-day culture period. Notably, the MGC-RGD group was the only 
group that did not show a significant decline in ASC viability over the course of the 
study, suggesting that the incorporation of the RGD peptide supported long-term cell 
viability. In contrast, poor viability was noted in the MGC-IKVAV group, suggesting that 
the selected peptide was not conducive for promoting ASC viability or retention 
following encapsulation in the 3-D MGC-based hydrogel system. The assessment of cell 
morphology showed that ASCs encapsulated in the MGC and MGC-IKVAV hydrogels 
maintained a rounded shape over the course of the study. In contrast, ASCs encapsulated 
in the MGC-RGD hydrogels presented a more elongated fibroblastic morphology within 
the superficial layers at 7 and 14 days in culture, providing evidence for cell-scaffold 
interactions between the ASCs and RGD motifs. The metabolic activity of the 
encapsulated ASCs declined between 24 h and 7 days for all hydrogel groups, and was 
then maintained throughout the course of the study. In addition, the metabolic activity 
was enhanced in the MGC-RGD group as compared to the MGC and MGC-IKVAV 
groups at 14 days, suggesting that the RGD peptide ligand may influence the metabolic 
functions of encapsulated ASCs over time. 
For aim 2, ASC function was probed in vitro by comparing the expression of 
angiogenesis-associated genes between ASCs encapsulated in the hydrogels versus 2-D 
tissue culture polystyrene (TCPS) controls cultured under simulated hypoxic conditions 
(2% O2) for 7 days. In general, the most notable differences were associated with 
culturing the ASCs in the 3-D hydrogels versus the 2-D culture conditions across all 4 
cell donors. More specifically, ASCs encapsulated in the hydrogels demonstrated a >2-
fold upregulation in gene expression for the secreted angiogenic factors hepatocyte 
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growth factor (HGF), vascular endothelial growth factor A (VEGFA), angiopoietin-like 4 
(ANGPTL4) and angiopoietin-2 (ANGPT2) relative to the TCPS controls. Furthermore, 
the extracellular matrix (ECM) protein collagen XVIII α1 (COL18A1), the matrix-
remodeling factor matrix metalloproteinase 14 (MMP14), and the cell adhesion 
glycoprotein integrin β3 (ITGB3) also demonstrated a >2-fold enhancement in gene 
expression in the hydrogel groups relative to the TCPS controls. In contrast, a >2-fold 
downregulation in gene expression was consistently noted across all 4 cell donors for the 
secreted factors thrombospondin-1 (THBS1), angiopoetin-1 (ANGPT1), connective tissue 
growth factor (CTGF) and fibroblast growth factor 1 (FGF1) in the ASCs encapsulated in 
the hydrogels as compared to the TCPS controls. While transcription for the majority of 
the analyzed angiogenic factors was not considerably influenced by the presence of the 
RGD or IKVAV peptides under the conditions in the study, these preliminary findings 
suggest that the 3-D microenvironment of the MGC hydrogel induced transcriptional 
changes in the ASCs under hypoxic conditions that may be favorable for a pro-
angiogenic response. 
For aim 3, cell retention and angiogenic-induction potential of ASCs encapsulated within 
the hydrogels was assessed in vivo after subcutaneous implantation into NOD/SCID mice 
for 14 days. A significantly higher number of ASCs were retained in the MGC-RGD 
hydrogels relative to the MGC-IKVAV hydrogels, consistent with the in vitro viability 
studies. While there was a trend for enhanced retention in the MGC-RGD group as 
compared to the MGC group, the difference was not statistically significant. These 
findings suggest that the base MGC scaffold alone provided a supportive 
microenvironment for ASC retention in vivo over the course of the study. With respect to 
the pro-angiogenic potential, ASC-seeded MGC and MGC-RGD groups enhanced 
murine CD31+ cell recruitment within the peri-implant region as compared to their 
corresponding unseeded controls, suggesting that the hydrogels were able to support the 
paracrine functions of ASCs to help establish accessory cell recruitment, a characteristic 
of a more pro-angiogenic microenvironment. In contrast, there was no difference in 
CD31+ cell recruitment between the ASC-seeded and unseeded MGC-IKVAV group, 
potentially due to the low cell viability and retention within these hydrogels. Assessment 
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of CD31+ EdU+ cells in the peri-implant region indicated that CD31+ cell proliferation 
was ongoing in all of the groups. Altogether, these findings suggest that the MGC and 
MGC-RGD hydrogels provide a cytocompatible microenvironment, supportive of ASC 
retention and accessory cell recruitment in vivo. 
The collective findings highlight the potential of the MGC and MGC-RGD hydrogels as 
cell-delivery platforms, capable of supporting the viability, retention and sustained 
function of encapsulated ASCs. In addition, evidence of the pro-angiogenic capacity of 
encapsulated human ASCs was provided through the in vitro and in vivo studies, lending 
support for their use in therapeutic applications to promote vascular regeneration. 
Ultimately, the work presented in this thesis contributes to the fields of stem/stromal cell 
biology, biomaterials and therapeutic angiogenesis. 
5.2 Future Recommendations 
Although the current project offers insight into the development of an injectable cell-
delivery platform for therapeutic angiogenesis, future studies should focus on optimizing 
the ASC viability, retention and function following encapsulation in the hydrogels. 
Continued refinement of the functionalization of the MGC hydrogels with peptides 
incorporating the RGD or IKVAV bioactive motifs, complemented with in vitro and in 
vivo studies to further assess ASC behaviour within the hydrogels, could help to establish 
a more effective cell-delivery vehicle. 
Previous studies have provided support for the IKVAV peptide in promoting cell 
attachment and proliferation.165,169,244 However, the current findings suggest that the 
inclusion of the 19-mer IKVAV peptide in the MGC hydrogels adversely impacted 
hydrogel cross-linking and the viability of encapsulated ASCs. Therefore, it would be 
beneficial to examine whether adjusting the length and/or hydrophobicity of the IKVAV 
peptide could provide a 3-D conformation that improves the ASC survival and better 
supports integrin-mediated cell attachment within the hydrogels. In addition, future 
studies could investigate the degree of RGD or IKVAV functionalization of the MGC 
hydrogels over a boarder range (e.g. 2.5%, 5%, and 10%), in order to delineate any 
concentration-dependent trends on ASC attachment, viability and metabolic function, as 
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observed in previous reports.141 Collectively, these studies will help to establish the 
appropriate peptide sequence and concentration required to improve ASC adhesion and 
retention within the hydrogels. 
The confocal imaging of ASCs encapsulated in the hydrogels in the current study allowed 
for the macroscopic assessment of ASC morphology following culture. Future studies 
should include more detailed immunohistochemial analysis to examine the changes in the 
cytoskeleton structure of the encapsulated ASCs. For example, ASCs could be stained for 
actin and vinculin at various time points (e.g. 7, 14 and 28 days), and analyzed through 
confocal imaging to validate the trends by more fully assessing cell spreading and focal 
adhesion formation. In order to better understand the regulation of integrins in ASCs 
during cell attachment, it would be of interest to examine the expression of various 
integrin subunits (e.g. α1, αV, β3, etc.) through immunohistochemical staining. This 
study may help define the predominant α/β subunits involved in the cell-scaffold 
interactions due to the presence of integrin-binding RGD or IKVAV motifs. 
While the metabolic activity of ASCs encapsulated in the hydrogels showed an initial 
decline across all groups, a rebounding trend was observed in the MGC-RGD group by 
day 14. Future studies should more fully probe this response by assessing the ASC 
metabolic activity at later time points (e.g. 28 days) to determine whether the bioactive 
peptide ligands in the hydrogels significantly enhance metabolic functions following 
long-term culture. In addition, the total dsDNA content in the ASC-encapsulated 
hydrogels should be assessed using the Quant-iT PicoGreen® dsDNA assay in order to 
validate the current semi-quantitative imaging data regarding the total cell number, and 
more fully assess whether the ASCs may be proliferating within the scaffolds, potentially 
in combination with Ki67 immunohistochemical staining. 
The high-throughput screening of the angiogenesis-associated genes in the ASCs 
encapsulated within the hydrogels showed that the expression levels of several key pro-
angiogenic genes were altered as compared to TCPS controls. Future studies could 
further probe the relevant genes through real-time RT-PCR and Western blotting of 
protein lysates to determine their regulation over the course of 14 or 28 days. The 
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conditioned medium from culturing the ASC-encapsulated hydrogels could also be 
examined through MultiPlex ELISA or proteomics analyses to assess whether detectable 
levels of factors are being secreted from the hydrogels over time. Furthermore, for a more 
controlled comparison between 3-D and 2-D culture conditions, future studies could 
probe the angiogenic response of ASCs seeded onto the surface of MGC, MGC-RGD or 
MGC-IKVAV hydrogels. Collectively, these studies would provide an in-depth analysis 
of the angiogenesis-associated secretory factors at the transcriptional and protein level. 
MSCs have been previously shown to maintain the expression of typical stromal cell 
markers following prolonged 2-D culture conditions.276 It would be of interest to 
investigate the MSC phenotype of ASCs following 3-D culture within the hydrogels. 
More specifically, the mRNA could be extracted from donor-matched ASCs prior to the 
encapsulation process, as well as after culture in the hydrogels for 14 or 28 days. The 
MSC marker expression could then be analyzed using a Human Mesenchymal Stem Cell 
RT2 Profiler™ PCR array to compare the stem-cell state of ASCs prior to and following 
3-D culture within the hydrogels.  
In terms of future in vivo work, the efficacy of the injectable ASC delivery strategy 
should be investigated in a murine femoral artery ligation (FAL)-induced hindlimb 
ischemia model.208 More specifically, ASC-loaded hydrogels could be injected 
intramuscularly into the hindlimb of NOD/SCID mice following FAL-induced hindlimb 
ischemia. Thereafter, the mice could be assessed in terms of limb reperfusion via Laser 
Doppler Perfusion Imaging (LDPI), functional limb improvement using a CatWalk™ 
system, and revascularization through more detailed immunohistochemical (CD31 and 
von willebrand factor) analysis. In addition, NOD/SCID/mucopolysaccharidosis type VII 
(MSPVII) mice could be used in a similar hindlimb ischemic model to allow for the more 
sensitive detection of transplanted viable ASCs in the ischemic tissue, as these mice lack 
beta-glucoronidase (GUSB) activity that is ubiquitously expressed in human cells.208 This 
approach would enable the assessment of ASCs using a calorimetric substrate for GUSB 
in order to localize viable transplanted cells, at single cell resolution, within or around the 
new blood vessel growth. Together, these investigations would aid in understanding the 
potential of the MGC-based ASC-delivery strategy to retain the transplanted cells, 
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promote angiogenesis, and facilitate functional recovery of ischemic tissues, as a next-
step towards clinical translation.  
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